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ABSTRACT 
 
 
 
Blocher-Smith, Ethan Charles. M.S., Purdue University, December 2013. Investigations 
of Lipid Metabolism in Yarrowia lipolytica. Major Professor: Dr. Robert E. Minto 
 
 
 
An investigation of the lipid metabolism pathway in the yeast Yarrowia lipolytica was 
conducted.  Yarrowia is an oleaginous ascomycete that is capable of growing on many 
different substrates, which derives its name from its high efficiency of growth on lipids. 
Once the exogenous lipids are converted into free fatty acids and internalized by the yeast, 
the primary mode of degradation is through β-oxidation mediated by the peroxisomal 
oxidases, or POX genes.  These enzymes catalyze the formation of a trans double bond, 
producing the trans-2-enoyl product.  Our study looked at the comparison of the Y. 
lipolytica prototrophic strain against a knockout of the Pox2 gene on the uptake, 
incorporation, and degradation of relevant fatty acids.  To construct this gene knockout, a 
novel gene deletion method using a combination of Cre recombinase and the AHAS* 
gene was synthesized, developed, and tested successfully.  This knockout system allows 
for serial deletion of genes with the use of only one resistance marker, with excision of 
the marker after selection. 
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CHAPTER 1. INTRODUCTION 
 
 
 
 Yarrowia lipolytica is an oleaginous ascomycetaneous yeast capable of producing as 
much as 50% lipid by mass in the wild type strain.  It derives the designation “lipolytica” 
from its inherent capability of growing on lipids as its sole carbon source.  While capable 
of growth on many nonstandard feedstocks, such as glycerol, soap wastes, or amino acids, 
the yeast rapidly accumulates lipids as TAGs (triacylglycerols) in specialized organelles 
called lipid bodies when cultured on media with a nutrient restriction.   While many 
dietary restrictions are capable of producing this result, such as low magnesium, sulfur, or 
oxygen concentrations, increased TAG accumulation is most conveniently accomplished 
through restriction of nitrogen content.   
 Once lipids are synthesized de novo or taken up from the media they will take one of 
three metabolic paths.  Some lipids, especially short chain fatty acids, will be degraded to 
acetyl-CoA for sustaining energy needs.  Other lipids will be modified for signaling or 
metabolic needs through elongation, desaturation, hydroxylation, or appropriate 
conjugation to a polar headgroup, such as phosphocholine.  Lastly, the remaining lipids 
and some of the altered lipids will be retained as either TAGs or stearoyl esters within 
lipid bodies. 
 This study examined each of these three lipid metabolic paths and the roles they play 
in lipid degradation and storage.  A molecular biology technique for repetitive gene 
knockouts based upon homologous recombination was established, using a single 
excisable resistance cassette and iterative growth. Additionally, investigations of the role 
of the peroxisomal oxidase genes aimed to find any differences in activity based on 
cis/trans isomerism, degree of unsaturation, and the location of the double bonds.   
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1.1  Overview of Fatty Acids 
 
1.1.1 What are Fatty Acids? 
Fatty acids (FAs) and fatty acid derivatives are key components in cell structure, 
signaling, and energy storage (1).  These derivatives, such as sphingolipids or 
phospholipids, form the membrane bilayer of the cell and TAG products like specialized 
organelles (2).  Fat stores of TAGs in specialized lipocytes or lipid bodies allow for easy 
accumulation and mobilization of excess energy (3).  Fatty acids may be used for protein 
modifications through acylation (4), modified to produce hormones like eicosanoids (5) 
or signaling compounds like platelet-activating factor (6), and utilized to both stimulate 
and study regulatory enzymes (7). 
FAs consist of an acyl tail of variable length capped with a carboxylic acid.  Many 
different varieties of FAs exist, typically ranging between four and twenty-eight carbons 
(8) in length but observed as long as 34 carbons in plant cuticular waxes (9).  Unmodified 
FAs have acyl chains of only methylene groups that are saturated with hydrogens and are 
known as saturated FAs.  Chemical modification of fatty acids for storage or use may 
introduce many other functional groups, such as halogen substituents, hydroxyl groups, 
alkenes, alkynes, epoxides, and many more.  Modifications like epoxides or multiple 
bonds result in an unsaturated FA, since the acyl chain is no longer saturated with the 
maximum number of hydrogens.   
In yeasts, the de novo synthesis of FA occurs within the cytosol.  As in most 
eukaryotes, the biosynthesis is carried out by a multifunctional fatty acid synthase 
complex which uses acetyl-CoA and malonyl-CoA to generate saturated fatty acids with 
chain lengths of typically 16-18 carbons (10).  Modifications of this synthesis, both 
through elongation and β-oxidation, will result in the varied chain lengths previously 
described. In addition, for ease of discussion fatty acids are subdivided into groups via 
chain length, irrespective of their additional functionalities (Table 1).  
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Figure 1: Structure of fatty acids. Caprylic, or octanoic, acid (A) is a saturated fatty acid.  The carboxylic 
acid is marked in red, with the hydrocarbon tail marked in black.  (E)-hept-2-enoic acid (B) is a 
monounsaturated trans fatty acid. The last lipid, α-linolenic acid (C) is a polyunsaturated FA, or PUFA. 
 
 
 
 
1.1.2 Fatty Acid Nomenclature 
Fatty acids are identified via three core systems: 1) trivial names; 2) IUPAC names; 
and 3) lipid shorthand notations.   While trivial names clearly designate the compound, 
such as oleic acid, they provide no description as to its structure. Conversely, IUPAC 
names are complete in their description, but awkward and unnecessarily long. To 
maximize information without data loss, many shorthand forms for lipids exist, of which 
this work will use (∆) notation.  Linoleic acid, properly known as (9Z,12Z)-octadec-9,12-
dienoic acid, may be easily abbreviated as 18:2∆9,12.  In this notation, represented here as 
A:B∆C, ‘A’ represents the length of the carbon chain in the FA.  ‘B’ gives the number of 
double bonds present in the chain, and ‘C’ gives the positions of those double  
bonds and any other alterations in the acyl chain.  This notation is highly useful with 
PUFAs, allowing the condensation of both stereochemistry and positioning into an easily  
Classification Chain length 
Short-Chain Fatty Acid (SCFA) ≤11 carbons 
Medium-Chain Fatty Acid (MCFA) 12-15 carbons 
Long-Chain Fatty Acid (LCFA) 16-18 carbons 
Very Long-Chain Fatty Acid 
(VLCFA) 
≥19 carbons 
  
  
  
Table 1: Fatty acid chain length 
classification. Most common FAs in 
this study are LCFAs. 
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deciphered form.  This notation assumes that, unless noted, all double bonds are in the 
cis-configuration. Any trans-double bonds are designated with the letter ‘t’ appended 
after their position identifier. Similarly, triple bonds do not contribute to the count of 
double bonds and are designated by the appending of the letter ‘a’ after their identifier.  
 
Figure 2: Fatty acid shorthand nomenclature.  The ∆ designation gives the position of the feature relative to 
the carboxy terminus.  The top and bottom structures may be named as 18:2∆9,12t and 18:1∆9,14a, respectively.  
An alternative nomenclature numbers from the opposite ω end, giving rise to common terms like ω-6 FA 
indicating an FA with a double bond at C6 from the ω end. 
 
1.1.3 Fatty Acid Desaturases 
 
1.1.3.1  Background on the Desaturase Family 
Fatty acid desaturases perform oxidative dehydrogenation of acyl chains.  
Prototypically, this enzyme family abstracts a hydrogen atom from two adjacent 
methylene groups to form a double bond.  While naturally occurring double bonds are 
almost entirely in the cis configuration, a small percentage of the double bonds produced 
by other biochemical paths exist as the trans isomers (11).  To perform their functions, 
this family requires two electrons, two protons (H+), and molecular oxygen for each 
double bond formed. Activated oxygen cleaves the stable C-H bonds with the electrons 
providing the reducing equivalents.  Once complete, the oxygen is reduced to water and 
the double bond has been installed (12). 
This family of enzymes is present in both eukaryotes and prokaryotes, providing 
essential functions in regulating membrane fluidity through the variable desaturation of 
its constituent lipids.  Desaturases are also central to the production of highly unsaturated 
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products for use in hormones, regulatory compounds, and compounds involved in anti-
inflammatory responses (1,13,14). Desaturases are capable of accepting a range of 
distinctively conjugated acyl substrates, contributing to their prevalence as specialized 
and compartmentalized processes regulating cellular lipid metabolism. Four classes of 
substrates have been characterized: acyl-CoAs, acyl-ACPs, complex acyl-lipids, and 
sphingolipids (15).  Desaturases are also specialized as to the location of the installed 
double bond, showing predominant regioselectivities such as ∆6, ∆9, ∆12, or ∆15.  
Certain diverged desaturases are even capable of forming alkyne bonds or hydroxylated 
products, through the desaturation of an alkene to form the carbon-carbon triple bonded 
product or alcohols. These subclasses are known as the acetylenases and hydroxylases, 
respectively (16-18). 
 
1.1.3.2  Diverged Desaturases – Acetylenases 
To date, all acetylenase enzymes characterized are membrane-bound desaturases 
which present the same characteristic motifs and hydrophobic regions as seen in other 
desaturases (19,20), including three His box motifs believed to be essential to catalysis 
(21).  Acetylenases have high sequence homology to FAD2, a gene first characterized in 
Arabidopsis thaliana by Okuley et al. (13) that converts oleic acid to linoleic acid (shown 
in Figure 3).  Studies by Reed et al. in 2003 showed a stepwise mechanism for the action 
of the ∆12-acetylenase Crep1 from Crepis alpina which was analogous to the well 
established action of FAD2 ∆12-desaturases (22).  Additionally, beyond the ability of the 
characterized CfACET gene from Cantharellus formosus to act as a ∆12-acetylenase, an 
additional ∆14 desaturation step has also been observed (16).  It is hypothesized that this 
function is in fact the result of action by endogenous ∆12 desaturase activity, which, due 
to the foreshortening of the C12-C13 distance by the alkyne bond, is capable of reaching 
C14-C15 to perform the desaturation step.  
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Figure 3: FAD2 function. The FAD2 abstracts the pro-R hydrogen at C12 first, then rapidly abstracts the 
pro-R hydrogen from C13, resulting in the double bond formation. 
 
1.1.3.3  Previous Investigations – Epa955 & Epa2161 
Recent thesis work presented by Anthony Ransdell from our lab looked at the 
function of two genes isolated from Echinacea purpurea.  E. purpurea has been shown to 
produce a number of acetylene-containing natural products, implying the presence of at 
least one ∆12-acetylenase. A BLAST screen of the E. purpurea transcriptome versus 
known acetylenases and desaturases resulted in the discovery of two genes of note. 
Epa955 and Epa2161 showed up as the top two hits, and both showed high sequence 
homology to well-characterized acetylenases as well as the presence of the three His box 
motifs and hydrophobic regions seen previously.  Both genes were cloned from 
Echinacea and inserted into plasmids for use in the yeasts Saccharomyces cerevisiae and 
Y. lipolytica.  To observe the function of the heterologous genes in Yarrowia, codon 
optimization was required.  Careful analysis of the metabolic products from expression 
cultures clearly indicated that both genes possessed the ∆12-acetylenase function, 
converting linoleic acid to crepenynate (18:1∆9,12a) in the crepenynic acid pathway 
(Figure 4).  The study clearly showed significant production of 18:1∆9,12a both with and 
without supplementation of its immediate precursor linoleic acid.  Supplementation of the 
strain transformed with active Epa955 and Epa2161 plasmids with crepenynate showed 
significant production of dehydrocrepenynate, strongly implying that the genes also 
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possess a ∆14-desaturase activity.  However, the strains of Yarrowia in use contained the 
native FAD2 ∆12-desaturase, limiting definitive characterization of the enzymes (23).  
 
Figure 4: The crepenynate pathway through dehydrocrepenynate, as originally proposed by Bu'Lock (24) 
  
1.2 Yarrowia lipolytica 
Yarrowia lipolytica is an ascomycete yeast which shows distinct dimorphism with a 
sexual stage (25). The genus Yarrowia is monotypic, thus the genus and species titles are 
unique and will be used interchangeably. Previously designated Candida lipolytica, the 
yeast draws its species name from the wide variety of lipid products on which it can grow.  
Y. lipolytica utilizes a wide range of carbon sources, including carbohydrates such as 
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fructose, mannose, or sorbose, lipids ranging from FFAs to TAGs, alcohols, glycerol (26), 
and even aromatic/organic pollutant compounds (27).  Y. lipolytica is capable of 
accumulating up to 50% of its dry weight as lipids in the prototrophic strain, leading to its 
classification as an oleaginous yeast (28).  While more recent studies have looked at 
atypical uses, such as bioremediation, industrial research has focused on 3 core goals: 1) 
production of rare or useful lipids (5); 2) manipulation of the lipid content profile to 
mimic biologically or economically relevant forms (29); and 3) increased accumulation 
of lipids for use in biodiesel production (30,31).  
Previous studies have resulted in high efficiency production of specialized 
compounds like polyhydroxyalkanoates (PHAs), polymers of 3-hydroxyacids that form a 
biodegradable and renewable synthetic alternative to petroleum-based plastics (32).  The 
peach-like perfume component γ-decalactone may be produced in Y. lipolytica from 
methyl ricinoleate (33,34), and many of the Kreb’s cycle intermediates may be excreted 
into the media (35).  Other studies have considered the viability of modified Yarrowia 
strains as a source of cocoa butter substitutes (29).  Still others have engineered strains 
capable of lipid accumulation as high as 80% of the dry weight (36).  Of the three goals, 
this project seeks to further capabilities in biodiesel production through increased 
understanding of the activities of lipid degradation mechanisms against a range of FA, 
MUFA, and PUFA compounds. 
 
1.2.1 Lipid Sources 
Yarrowia produces, accumulates, and degrades a wide range of lipids.  These lipids 
are initially produced through one of two methods: de novo synthesis of new lipids from 
acetyl- and malonyl-CoA, or accumulation of exogenously fed lipids. 
 
1.2.1.1  De novo Lipid Synthesis 
 Unless grown on a lipid substrate, de novo lipid synthesis accounts for the vast 
majority of lipids produced in Yarrowia. Acetyl-CoA and malonyl-CoA are transferred to 
ACP, condensed to form the initial 3-ketobutanoyl-ACP product with the release of CO2 
and one ACP.  The acyl conjugate is then reduced to the alcohol, dehydrated to form a 
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trans double bond, and lastly hydrogenated to form the butanoyl-ACP product in the first 
FA synthesis cycle.  This cycle is then repeated, incrementing the chain by 2 carbons 
until the desired final length is achieved. The product FAs, heavily skewed in favor of 
16:0 and 18:0 (11), are then either degraded or modified/stored. This process is illustrated 
in Figure 5.  Yarrowia possesses a number of qualities uncommon to most yeast species 
that encourage the production of lipid products.  Comparative analysis of oleaginous 
versus non-oleaginous yeast and fungi by Vorapreeda et al. in 2012 (37) revealed 
alternative routes to produce acetyl-CoA.  The oleaginous strains studied, Y. lipolytica 
and three others, showed the capability to degrade fatty acids through mitochondrial β-
oxidation, an ability analogous to peroxisomal β-oxidation but that was not observed in 
the non-oleaginous species.  In addition, the oleaginous strains could degrade leucine as 
well as lysine to acetyl-CoA.  While the non-oleaginous species could degrade lysine to 
glutaryl-CoA, only this oleaginous species has been shown to possess the enzymes 
necessary to modify glutaryl-CoA into acetyl-CoA.  These alternative pathways integrate 
otherwise isolated metabolic paths to funnel into acetyl-CoA, which can be funneled into 
lipid production (37).  
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Figure 5: De novo lipid synthesis. While other capabilities deviate notably, especially the specialized ways 
oleaginous organisms produce acetyl-CoA from nonstandard sources, the core de novo anabolic pathway is 
the same as in S. cerevisiae. 
 
1.2.1.2  Extracellular Lipid Degradation and Uptake 
While de novo FA synthesis accounts for much of the lipid content, Yarrowia is 
especially efficient in accumulating exogenously fed extracellular lipids.  To prepare the 
lipids, a wide range of lipases are actively secreted into the media, which hydrolyze the 
ester linkages in TAGs and other lipid derivatives to produce free fatty acids (35).  
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Yarrowia makes and excretes such a high level of useful lipases that strains have been 
engineered to industrially produce these enzymes (35,38,39). Its species name lipolytica 
is entirely due to this mechanism, since without the range of lipases to degrade the lipids 
into FFA, the exogenously fed lipids could not be transported or utilized. These newly 
freed FFAs are then taken up through active transport mechanisms into the cytosol of the 
cell, where they may be degraded or modified/stored. 
 
1.2.2 Lipid Alteration and Storage 
Yarrowia contains highly active ∆9 and ∆12 FA desaturases, both of which have 
activities clearly shown in the yeast’s major products.  When the overall lipid profile 
from the wild type Y. lipolytica strain is analyzed after growth in a standard medium such 
as YNB, 85-90% of the total lipid content is comprised of five fatty acids: 16:0, 16:1∆9, 
18:0, 18:1∆9, and 18:2∆9,12 (31).  This behavior is maintained in minimal media with a low 
C/N ratio, such as with growth in high concentrations of glucose (40,41).  Since 16:0 and 
18:0 are the dominant products from FA synthesis, it is unsurprising that they and their 
direct desaturation products comprise the majority of stored lipid.  Once the lipid acyl 
chain has been altered as necessary through desaturation or other modification processes, 
the products are processed into their final storage forms through one of two paths, as 
shown in Figure 6. 
 Once the synthesis is complete, the final SE and TAG are accumulated in the lipid 
body, or bodies. Depending on the growth conditions, Yarrowia may produce one or 
several large lipid bodies, or many small ones. Total lipid content in the lipid body is 
between 80-90% TAG by weight, with the remainder being SE and trace amounts of FFA 
(42,43). The lipid body is enclosed in a phospholipid monolayer, studded with proteins 
needed to remobilize the neutral lipids and degrade them back to FFAs to enable β-
oxidation (3,44).  This process is illustrated in Figure 7. 
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Figure 6: SE and TAG synthesis. The synthesis of the SE is achieved through an acyltransferase, producing 
the neutral lipid. To form the TAG products, DHAP is converted into glycerol-3-phosphate. The resulting 
G-3-P is condensed at the sn-1 position with the acyl-CoA to form the phosphorylated monoacylglycerol. A 
second acyl-CoA is then esterified onto the glycerol backbone, and the glycerol is dephosphorylated, 
forming the DAG. Finally, the last acyl chain is installed through several acytransferase paths, forming the 
TAG (31). Genes shown: Gut2, G-3-P dehydrogenase; Gpd1, G-3-P dehydrogenase, forms G-3-P from 
DHAP; Sct1, G-3-P acyltransferase; Slc1, 1-acyl G-3-P acyltransferase; PAP, PA phosphohydrolase; Dga1, 
diacylglycerol acyltransferase; Lro1, a lecithin cholesterol acyltransferase-like gene; Are1, Acyl-CoA:sterol 
acyltransferase 
Total lipid content and citric acid produced is enhanced when necessary nutrition is 
limited. Because of this, growth is typically performed in media with a high C/N ratio 
that enhances the conversion of carbohydrates into lipids (45).  By providing an excess of 
the carbon source and harvesting cells prior to its exhaustion as a foodstock, analysis of 
cultures can identify conditions with the maximal lipid content and without alteration of 
its cellularly regulated lipid ratios. 
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Figure 7: The lipid body. The outer phospholipid monolayer is studded with useful proteins for 
mobilization (in green and orange), while the inner core consists of the TAGs (in blue) and the SEs (in red).  
 
1.2.3 Lipid Degradation 
Yarrowia will degrade lipids either for energy or to produce more of a desired 
regulatory/storage product.  Mobilization of the stored lipids happens during the 
exponential growth phase for membrane lipid synthesis, during the stationary phase upon 
nutrient depletion, and once exiting starvation and entering the vegetative state (31).  
Lipid stored as TAGs and SE are hydrolyzed to form FFA that is shunted off for synthetic 
purposes or proceeds through β-oxidation to form acetyl-CoA (46).  Unlike in mammals, 
yeast β-oxidation occurs entirely in the peroxisome without any involvement of the 
mitochondria, although Yarrowia does contain most of the enzymes needed for 
mitochondrial β-oxidation (41). While the hydration and oxidation steps are performed 
by one multifunctional enzyme complex (MFE1) and there is only one peroxisomal 
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thiolase, Yarrowia possesses a range of six different peroxisomal oxidases, or POX genes 
(31).  This suite of genes, designated as POX1, POX2, POX3, POX4, POX5 and POX6 
(previously named Pox2like for its discovery via sequence homology), work together in  
  
Figure 8: Peroxisomal β-oxidation. Note that as the acyl chain shortens, the involvement of Pox isozymes 
will change due to chain-length specificity. 
 
concert to perform β-oxidation.  The POX genes are translated as separate polypeptides 
in the cytosol, but will self-assemble into heteropentameric complexes prior to their 
import into the peroxisomes (47).  Of two of the Pox genes products, POX2 and POX3, at 
least one must be present to achieve functional assembly and targeting the complex to the 
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peroxisome.  If both of these genes are knocked out, the complex will not form and the 
polypeptides will remain separate and in the cytosol; Pox monomers are incapable of 
penetrating the peroxisome (47).  Each POX has a differing specificity, with well-defined 
substrates found for 4 of the 6 genes. POX1 and POX6 both have specific activity against 
dicarboxylic acids, POX3 is a short chain oxidase for FA chains C3-C10 (48,49), and 
POX2 is a medium chain oxidase acting on C8-C14 acyl groups (50).  POX4 and POX5 
have a general nonspecific binding across saturated FAs between C4 and C16 (51,52); 
however, a recent study looking at the viability of PHA production demonstrated a high 
activity of POX5 against the odd chain LCFA 17:1∆10 (32).   
 Unlike peroxisomal β-oxidation in other higher organisms, the peroxisomes in 
Yarrowia will degrade lipids all the way to acetyl-CoA (Figure 8). In the case of odd-
chain fatty acids, the degradation will be the same but the final product will be propionyl-
CoA.  Unsaturated lipids are either isomerized to form the trans-2-alkene or the double 
bond location is isomerized if necessary to allow the progression of normal β-oxidation 
(41).
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CHAPTER 2.  KNOCKOUT CONSTRUCTS AND CRE-AHAS* 
 
 
 
 Core to the completion of the studies detailed in this thesis is the production of 
engineered gene knockout strains of Y. lipolytica.  Successful implementation of this 
technology requires a system for rapid and consistent gene knock-outs and knock-ins 
with clear, testable markers to select and identify transformants and integration sites. The 
limitations presented by Y. lipolytica arise from a system that can be screened with few 
effective antibiotics and few standard resistance markers available.  Lastly, this 
transformation system must provide an easy and testable way to be removed and/or 
reused effectively. 
 This chapter details the development of pCre-AHAS* and the biotechnologies in use, 
production of the final plasmid and genetic constructs, and initial testing of the system on 
the FAD2 gene.  Special emphasis is placed on the design factors, intended to highlight 
the reasoning behind key decisions.  While similar in some aspects to the classical 
method of using LEU2 and URA3 knockouts (53), our method, an extension of the work 
by Fickers et al. (54), allows for high specificity and selectivity through all steps of both 
construction and use. 
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2.1 Background 
 
 
2.1.1 Why Does Yarrowia lipolytica Require a Custom Knockout Strategy? 
Besides the obvious requirement for organism-specific initiators and terminators for 
any genes, Y. lipolytica has a high codon usage bias, requiring the codon optimization of 
relevant genes.  In addition, Yarrowia is resistant to the majority of the commonly used 
antibiotics, eliminating a wide range of typical markers (55,56).  Of these, only 
hygromycin B (hygB, shown hereafter as hyg) is highly effective (57), along with the 
much less common bleomycin/phleomycin group.  While mutants with blockages in 
required metabolic processes have provided a few paths to gene manipulation, our 
eventual intention of multiple gene knockout products would require the use of many 
markers.  Even though success has been seen with the use of the classical one gene-one 
marker knockout approach, the production of useful heavily modified strains, such as that 
reported by Dulermo and Nicaud (36) would require 8 markers, far more than exist.  To 
circumvent this difficulty, a knockout system must optimally reuse one resistance cassette, 
with removal after each confirmed knockout.  This criteria is met by the use of the Cre-
AHAS* system, which operates with high specificity and an excision rate of over 98% in 
the seminal study (54). 
 
2.1.2 Genetic Technologies in Use 
 
2.1.2.1  Cre Recombinase 
 Cre recombinase is a topoisomerase derived from the P1 bacteriophage.  It catalyzes 
the site-specific recombination of DNA between loxP sites, with the result dependent on 
the site orientation (58).  The loxP recognition site is a 34-bp sequence with two 13-bp 
inverted repeats flanking an 8-bp spacer region that confers directionality (59).  Three 
distinct configurations exist (Figure 9), but for our purposes we will use the orientation 
leading to deletion exclusively (60,61).  Once the DNA segment is deleted, the product 
will still contain one active loxP site, which could cause problems upon a secondary 
transformation.  To prevent this difficulty, two modified loxP sequences dubbed loxLE 
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and loxRE (so named as the left and right elements) will be used. These mutants are 
designed so that upon the catalytic action by Cre recombinase, the product loxP site 
formed is unrecognized by the recombinase and is thus inactive (62).  
 
Figure 9. The functions of Cre recombinase. Most studies use Cre recombinase for genetic deletions. 
However, arrangement A allows for gene inversion and option B translocation, can in fact join together two 
segments of DNA into one cohesive strand. Figure courtesy of The Jackson Laboratory, Bar Harbor, 
Maine.  All rights reserved (60). 
 
By flanking our resistance cassette with the loxLE and loxRE sites, transformation 
with a plasmid to produce Cre recombinase will excise the desired sequence with no 
effect on the remaining genome beyond the short loxLR scar.  However, without loss of 
this Cre-containing plasmid and an easy way to confirm its loss, iterative transformation 
will be impossible as the recombinase will excise the resistance prior to selection.  To 
compensate for this, we have utilized an independent chlorimuron ethyl (CME)-resistant 
AHAS marker for the Cre-bearing plasmid. 
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2.1.2.2  CME and the AHAS gene  
 CME, or chlorimuron ethyl, is a sulfonylurea herbicide used on a number of plants 
for weed control.  CME and its class of herbicides are of special interest, as they provide 
no harm to humans or animals, demonstrating little toxicity in birds with an acute toxicity 
of 2,510 mg/kg, and low toxicity to fish and invertebrates (63). While initial studies 
demonstrated no oncogenicity, teratogenicity, or mutagenicity (63), further research has 
led to its classification as a possible human carcinogen by DuPont (64). However, the 
previous results are upheld along with no carcinogenicity seen in tested mammals, thus 
the only reported threat to humans is skin and/or eye irritation.   
CME inhibits the action of the acetohydroxyacid synthase (AHAS), thus arresting 
branched-chain amino acid 
synthesis (65).  AHAS, also 
known as acetolactate synthase, is 
a transketolase which condenses 
two molecules of pyruvate to 
form carbon dioxide and 
acetolactate, the key first reaction 
in the synthesis of valine and 
leucine. AHAS also can convert 
α-ketobutyrate to α-aceto-α-hydroxybutyrate, a key step in the production of 
isoleucine from threonine.  Without the ability to synthesize these key amino acids, the 
organism in question can not survive in minimal media that does not contain Val, Leu, 
and Ile (66).  AHAS is present in bacteria, fungi, algae, and plants, and has been shown to 
be present in Yarrowia (67).  Interestingly, several point mutations in the AHAS gene, 
including P197L and W497L, confer strong resistance to sulfonylurea herbicides (68).  
After verifying the activity of CME against our Yarrowia strain, the presence of this 
AHAS W497L mutant (designated AHAS*) on the Cre recombinase plasmid will allow 
selection of transformants via both CME and hyg.  As the Cre recombinase works, the 
resistance to hygromycin will be deleted, allowing for selection through replica plating to 
identify colonies that grow in CME and not with hyg.  Subsequent periods of growth in 
Figure 10: The structure of chlorimuron ethyl.  While 
subclassified in a number of specialized categories, it derives the 
sulfonylurea title from its characteristic linker of the two 
aromatic groups. 
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nonselective media will allow for the eventual loss of pCre-AHAS*, reinstating 
susceptibility to CME once more.  While all of the genes and transcriptional sequences 
existed separately, their assembly to a single functional construct was performed using a 
high-efficiency BP/LR Clonase reaction for easy integration. 
 
2.1.2.3  BP/LR Clonase Reactions 
Gateway® Technology (Invitrogen) is driven by the BP and LR Clonase reactions, 
catalyzed by enzymes derived from the lambda bacteriophage (69).  Use of this system 
allows high efficiency transfer of a genetic sequence tagged with the transfer sites while 
maintaining orientation.  The BP and LR reactions are so named due to the recognition 
sites which are targeted, namely attB, attP, and so on.  These sites consist of 15-bp core 
regions that are homologous in all of the sites, flanked by selective targeting sequences. 
In the original lambda phage, the phage DNA, flanked by attP sites, is switched via the 
BP Clonase reaction with a segment of DNA in the bacteria it infects, flanked by attB 
sites. This allows the insertion of the phage DNA into the bacterium through the 
 
 Figure 11. The Gateway® technology Clonase reactions. These two reactions constitute a two-step process, 
allowing for the use of any plasmid as the donor or destination vector, so long as it contains the appropriate 
Gateway sequence. The final expression clone from reaction B will have inactive attB sites. Image courtesy 
of Life Technologies (70). 
lysogenic pathway, where it remains dormant.  Once ready for excision from the 
bacterium through the lytic pathway, the phage DNA, now flanked by the attL sites 
produced through the insertion, will react with the attR sites and swap back the DNA 
through the LR Clonase reaction, reforming the attB and attP sites.  In each case, the 
reaction occurs with homologous crossover at the core 15-bp sites, and the exchange of 
the DNA strand and half of each targeting sequence.  This process is conservative, 
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directional, and able to be performed on DNA in any configuration (supercoiled, linear, 
etc.), albeit with differences in efficiency (71).  
The proprietary patented version of this system from Invitrogen has a number of 
alterations from the original, including modifications to remove stop codons, to 
accommodate all reading frames, and to prevent secondary structure formation in the 
single stranded form at the attB sites. Additionally, the sites have been modified to ensure 
directionality; each attB site will react with only one of the attP sites, and vice versa.  
The donor vector and Gateway for use in the destination vector have both ccdB 
(discussed in the next section) and the CmR gene, conferring resistance to 
chloramphenicol (abbreviated Chl).  Lastly, the final LR Clonase reaction produces 
inactive sites, guaranteeing irreversibility and guarding against any potential issues in 
vivo (70).   
For our purposes, the desired gene (in this case, AHAS*) was synthesized as an attB-
flanked PCR product and reacted with the provided donor vector, producing an entry 
clone.  An appropriate Gateway sequence is inserted into the desired final plasmid, 
producing the destination vector. Finally, the entry clone and destination vector are 
reacted to produce the desired expression clone, which is ready for use.  
 
2.1.2.4  Transformant Selection via ccdB 
The ccdB gene, originally found in Escherichia coli, encodes CcdB, an F plasmid 
protein product that binds DNA gyrase.  Once bound, the gyrase is inactivated, promoting 
the breakage of DNA and resulting in cell death.  While this complex may be separated 
by another F plasmid protein, CcdA, the rapid demise of any E. coli strains containing the 
ccdB gene can be used as a transformation selection mechanism (72).   Consider a 
situation as is shown in Figure 11A, where the entry clone is produced.  After the BP 
Clonase reaction a total of four different products will be present: the unreacted PCR 
sequence, the unreacted donor vector, the reacted entry clone, and the byproduct strand.  
Of these, two contain the ccdB gene, resulting in cell death upon transformation.  To 
select between the remaining two options, the donor vector plasmid contains the 
kanamycin resistance gene. Thus, even with transformation of the reaction mixture 
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directly into E. coli cells, growth on Kan-containing plates will result in growth of only 
cells containing the entry clone.  Similarly, the destination vector contains the Chl 
resistance and a second resistance gene, which in our case codes for ampicillin resistance.  
After performing the LR Clonase reaction, transforming into E. coli, and growing on 
plates with Amp, all surviving product colonies should only contain the final expression 
clone (70). The published efficiency of this system is ≥99%.  
 
2.1.3 Design Summary 
The initial gene knockout was performed using a designed knockout construct (Figure 
12).  Using 1-kb untranslated regions (UTRs) on either side to target the appropriate gene,  
  
Figure 12: Knockout construct diagram.  Note hph confers resistance to hygromycin B, and that the 
specialized loxP mutant sites are in use. 
the sequence was replaced via homologous recombination through double crossover.  The 
presence of this construct was verified by growth on YPD + hyg followed by verification 
of the location by PCR amplification. A consistent distribution of primer-binding sites 
(Figure 13) was designated that allow for the selective amplification of relevant products 
for all knockouts.  Using this approach, three amplifications would be sufficient to 
conclusively demonstrate this homologous recombination displacing the target gene: 1) 
Amplification of HPH3!C. This amplification, entirely within the inserted construct, 
pCR4-­‐TOPO	  vector	  
1kb	  UTR	  6lanking	  region	  
loxRE	  site	  
hph	  gene	  
loxLE	  site	  
1kb	  UTR	  6lanking	  region	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will verify the integrity of the drug resistance cassette.  2) Amplification of HPH3!F.  
This amplification runs from the center of the construct out into the neighboring genome 
and will provide support that the recombination was correctly targeted.  3) Amplification 
of HPH4!E.  Analogous to the second amplification, isolation of a properly sized PCR 
product will further support disruption of the intended locus by probing sequence 
adjacent to the opposite end of the construct.
 
Figure 13: PCR primer sites in and around the knockout construct. Note that the construct extents 1kb from 
either end of the hph gene. 
The remainder of the design summary, previously described herein, is summarized in 
Figure 14.  The product pCre-AHAS* will be usable with any other gene knockout 
constructs using this same hph/loxP design.  In addition, after loss of pCre-AHAS*, a 
knockout strain may then integrate a second hph construct through homologous 
recombination, which may in turn be excised through transformation with pCre-AHAS*. 
This iterative process is limited only by the number of hph constructs synthesized. 
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2.2  Materials and Methods 
 
2.2.1 Production of Entry Clone 
Wild type Y. lipolytica (ATCC 20460) was grown on YPD at 28°C.  Genomic DNA 
was released from cells via NaOH preparation similar to that given by Wang et al. (73). A 
small clump of fresh cells (1 mm3) were added to 10 µL of 20 mM NaOH and heated to 
99 °C for 15 min.  The cells were then rapidly centrifuged, resulting in a solution  
 
Figure 15: Map of pAHAS* after BP Clonase rxn. 
containing the desired DNA. The W497L mutant AHAS was then amplified in two steps 
from the gDNA using specialized primers containing the attB sequence flanking either 
end of the gene and primers to install the point mutation.  After sequencing to confirm its 
identity and the installation of the desired mutation, the AHAS* gene was reacted with 
pDONR221 via the BP Clonase reaction (70) to produce the entry clone, as seen in 
Figure 15.  This clone was prepared by Dr. Robert Minto, prior to my involvement in this 
project. 
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2.2.2 Preparation of Gateway Plasmid 
Unless otherwise noted, each product plasmid was transformed back into RbCl2 XL1 
Blue chemically competent E. coli cells to prepare freezer stocks, then fresh cultures of 
each were grown and the plasmids were prepared using the alkaline lysis Wizard 
miniprep kit from Promega. The Cre recombinase gene had been PCR amplified from 
pSH65 (graciously provided by Prof. M. Goebl, IU School of Medicine, Indianapolis, IN) 
and ligated into the BamHI/NotI sites in the pY5 plasmid (a gift from E. Cahoon, Univ. 
Nebraska, Lincoln, NE) (Figure 16).  While retaining the ARS 18 as the Yarrowia 
promoter sequence, it was advantageous to replace the no longer needed LEU2 gene with 
a Gateway linker sequence to allow the flexible installation of a new selectable marker.  
A mutation at position 2910 was added using the QuickChangeII procedure to inactivate 
the EcoRI restriction site, which was confirmed via digests with EcoRI (Figure 17).  
When initial attempts with EcoRI/SphI double digests were unsuccessful despite 
optimization of the digestion conditions and the addition of SphI restriction sites via 
mutagenesis, digestion with EcoRI alone only excised half of the LEU2 gene (positions 
5545-6507), as shown in Figures 18-21. This was also shown via cycle sequencing 
(Figure 22). After repeated failures in digesting the plasmid with EcoRI and SphI, 
together or stepwise, other options were considered, leading to the ultimate installation of 
an EcoRI site adjacent to the ARS 18 promoter.  With insertion of this site via a point 
mutation (T4309A), the product plasmid was checked via cycle sequencing (Figure 23).
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Figure 16: pY5-Cre plasmid map. This plasmid is the result of ligating Cre recombinase, excised from 
pSH65, into the standard Yarrowia plasmid pY5 (plasmid courtesy of R. Minto). 
  
Figure 17: Confirmation of EcoRI site deletion. Note that in the deletion strains only one ~7 kb band is 
visible (the 1 kb band is too faint to be seen), but the plasmid prior to site directed mutagenesis led to two 
excision products (~2.6 kb and 5.5 kb).
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Figure 18: Plasmid resulting from the excision of half of the LEU2 gene from pY5-Cre. The Muta 2S title 
is derived from the second SphI site that was engineered into the LEU2 gene by site-directed mutagenesis. 
 
Figure 19: Restriction digests of pY5-Cre Muta 2S-Cut. Note the large amount of uncut plasmid from the 
SphI digest. Both SphI and EcoRI individually show effective digests, but the double digests led to aberrant 
bands. Due to this irregularity, the plasmid was also checked with a second battery of digests.
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Figure 20: pY5-Cre Muta 2S-Cut with selected restriction sites denoted. 
 
Figure 21: Alternative restriction digests of pY5-Cre Muta 2S-Cut. All of the fragment lengths correspond 
exactly with those predicted from the plasmid restriction map, thus supporting its identity.
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Figure 22: Selected sequencing data confirmed the pY5-Cre Muta 2S-Cut sequence. This region was 
selected due to the overlap of the two sequenced regions. Excepting the installed mutation, only 2-3 
possible sequence changes versus the GenBank sequence for pY5-derived regions of the plasmid were 
observed throughout the total sequence area. 
 
 
 
Figure 23: Sequencing of T4309A mutant demonstrated the insertion of the EcoRI site. This plasmid was 
denoted as pY5-Cre Muta 2E/2S, due to the two altered EcoRI and two SphI restriction sites. Note the 
presence of the desired mutation in red. 
 The resulting plasmid was also checked directly by an EcoRI digestion (Figure 24).  
To complete the replacement of the LEU2 gene with the Gateway linker, this plasmid 
was digested in excess with EcoRI, heat inactivated, then the DNA ends were blunted. 
This final DNA strand was treated with Antarctic phosphatase to limit recircularization. 
Once the phosphatase was inactivated, the DNA was mixed with Gateway RfA from the 
Invitrogen Gateway Kit per published instructions (70), and the two were joined using T4 
DNA ligase.  The heat-inactivated ligation mixture was transformed into Invitrogen One 
Shot® ccdB Survival™ T1R competent cells and plated on prewarmed LB+Amp+Chl 
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plates.  Initial growth of 2 
days at 37°C resulted in no 
colonies, likely due to the 
presence of 3 very strong 
selection factors (Amp, Chl, 
and ccdB). The plates were 
allowed to sit out at room 
temperature over two 
additional days, resulting in 
hundreds of colonies. Of 
these, 64 colonies were 
screened via shaken growth 
in LB+Amp+Chl liquid 
media overnight at 37 °C, 
250 rpm.  In total, 7 of these 
cultures grew, and the best 
four were analyzed via 
boiling miniprep.  The final 
plasmid DNA was tested via 
digestion with MluI and SmaI (Figure 25), showing two plasmids (Gateway #8 and 
Gateway #9) with the RfA gateway in the correct orientation (Figure 26), and two 
(Gateway #15 and EG #24) with the RfA gateway ligated in the reverse direction (Figure 
27).  All four strains were cultured and duplicate freezer stocks of each were made and 
stored in the -80 °C freezer.  After sequencing of the Cre recombinase gene to ensure no 
alterations and of the Gateway cloning site as final confirmation of positioning, Gateway 
#9 was chosen as the verified destination vector. 
Figure 24: Digests of Muta 2E/2S strains with EcoRI.  Plasmid 
#5, which was the precursor to the addition of the EcoRI site 
near base 4310, merely linearized, but DNA from plasmid #6 
successfully produced two fragments of the correct size. 
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Figure 25: Confirmatory digests of the Gateway destination vectors. Due to lightness the bands for 
Gateway #15 and EG #24 are marked. SmaI appears to have poor activity because both the uncut and 
singly cut plasmid appeared for each digest. 
 
Figure 26: Map of the Gateway destination vector. 
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Figure 27: Map of Gateway destination vector with inverted Gateway cassette. 
 
2.2.3 LR Clonase Reaction 
The marker gene from pAHAS* #11 was transferred into pY5-Cre Gateway #9 with 
the LR Clonase reaction using the published procedure (70).  The resulting reaction 
mixture was transformed into supercompetent Omnimax® 2 T1R cells (Invitrogen) and 
plated on LB+Amp plates, which were incubated at 37 °C.  A total of four colonies 
appeared overnight, all of which were picked and cultured in liquid LB+Amp overnight 
at 250 rpm, 37 °C.  Plasmid DNA was isolated and digested with three restriction 
enzymes for characterization (Table 2; Figures 28, 29).  Clone LR2 clearly showed the 
appropriate bands and was thus renamed pCre-AHAS*.  Cycle sequencing of the LR2 
product (pCre-AHAS*) was also used to verify the sequence fidelity (not shown).  
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Table 2: Expected band sizes for restriction digests of pCre-AHAS*. 
Restriction Enzyme NcoI AflII NotI 
Expected bands (bp) 5635 7608 8998 
 1947 1390  
 1290   
 126   
 
 
  
Figure 28: Map of pCre-AHAS* plasmid. 
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Figure 29: Characteristic digests of the product strains from the LR Clonase reaction. While LR1 and LR4 
appeared to have the same product, its identity was not pCre-AHAS* based on the plasmid map. Only LR2 
showed the appropriate bands. 
 
2.2.4  Testing of CME Herbicide 
To be able to utilize the AHAS* gene as a selection marker, an efective working 
concentration for CME needed to be determined. Since colonies wil be grown in both 
liquid and solid cultures, both of these dosages were determined separately. With its high 
CME solubility of 70.5 mg/mL and low toxicity, acetone was chosen for the preparation 
of concentrated stock solutions (63). Other solvents capable of dissolving CME 
eficiently, such as methylene chloride (153 mg/mL), acetonitrile (31.0 mg/mL), and 
ethyl acetate (23.6 mg/mL) presented toxicity concerns for in vivo experiments, while the 
solubility in n-hexane was far too low for use as a stock solution (0.06 mg/mL). To avoid 
evaporation issues when pipeting smal volumes of the CME in acetone, a secondary 
stock solution of CME in ethanol (reported solubility of 3.92 mg/mL (63) was used for 
lower concentrations. 
 
2.2.4.1  Liquid Cultures 
In total, three studies were performed to determine the required CME concentration in 
liquid cultures. For each study, the prototrophic Yarrowia ATCC 20460 strain was 
cultured overnight in YPD at 28 °C, 240 rpm for use as a starter. The cel density of this 
starter was manualy counted alowing the culture flasks to be inoculated with 4.0x103 
cels per mL of CM-leu+dex. After inoculation with the cels, an appropriate amount of 
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CME was added to each flask and the culture was incubated at 28 °C, 240 rpm. The 
flasks were removed from the incubator at regular intervals and sampled, with the cell 
density measured spectrophotometrically.  The sampled volume or, as necessary, a 
dilution of the sample to remain within the dynamic range of the spectrophotometer was 
analyzed by A600 absorption.  The results of these studies are shown in Figures 30-32.  In 
total, while dosing each set of replicates (prepared from the same starter), the only 
significant growth was seen for cultures with ≤1 µg/mL, and marginal growth in cultures 
at 5 µg/mL. To ensure absolutely no growth of contaminant colonies, 20 µg/mL was 
selected as the standard liquid culture CME concentration. 
 
 
Figure 30: CME feeding in liquid media - trial #1. This trial used high [CME], with the CME stock solution 
in acetone. After 42 hours, no growth was seen from any of the CME-containing cultures.
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Figure 31: CME feeding in liquid media - trial #2. This trial used low [CME] and the CME stock solution 
in EtOH. The EtOH control was fed pure EtOH at the maximum concentration used. After 42 hours, no 
significant growth was seen from any of the CME-containing cultures. 
  
Figure 32: CME feeding in liquid media - trial #3.  After 90 hours of culturing, significant growth was seen 
for [CME] ≤1 µg/mL, and detectable growth was observed for 5 µg/mL CME. As before, the acetone 
control was fed the same volume as present in the most concentrated flask.
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2.2.4.2  Solid Agar Plates 
To test the necessary CME concentration in solid media, a series of CM-
leu+dex+CME plates were poured, with concentrations ranging between 1-150 µg/mL 
CME.  A freshly cultured overnight Yarrowia prototroph starter was diluted 1:20 in TE, 
and 150 µL of the dilution was pipetted to each plate and spread across the surface via 
glass spreader bar.  The plates were incubated 48 hours at 28 °C and the resulting 
colonies were counted  (Table 3). Since 100 µg/mL marks the concentration that 
suppressed essentially all growth and allowed the preparation of homogeneous plates, it 
was selected as the standard concentration for CME in solid media.   
 Table 3: Growth of the Yarrowia prototroph on CME 
in solid agar. While the higher concentration of 150 
µg/mL resulted in no colonies, both sets of plates 
contained precipitated CME crystals.  
 
 
 
 
 
 
2.2.5 Testing of pCre-AHAS* 
 
2.2.5.1  Production of FAD2 KO 
The synthesis of the FAD2 KO construct, as with all of the other Yarrowia gene KOs, 
was completed in conjunction with the IUPUI Undergraduate Research Mentoring 
(URM) program. Several undergraduates, under the coordination of Dr. Brenda 
Blacklock, assisted in the synthesis, assembly, and transformation of these hyg-selected 
knockout cassettes, with the majority of the successful products produced by Dr. 
Blacklock and Paola Fernandez.  The FAD2 KO construct was synthesized and verified 
through PCR amplification and cycle sequencing by Dr. Blacklock.  It was subsequently 
transformed into Yarrowia with homologous recombination, and the insertion site was 
verified by PCR amplification.   
CME concentration Colony Count 
1 µg/mL Lawn – DNR 
10 µg/mL Lawn – DNR 
25 µg/mL ≥400 colonies 
50 µg/mL ≥100 colonies 
100 µg/mL 6-8 colonies 
150 µg/mL 0 colonies 
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2.2.5.2  Confirmation of AHAS* Resistance to CME 
 To demonstrate the insensitivity of AHAS* to CME, the prototrophic Yarrowia 
strain was transformed with pCre-AHAS* via the procedure described by Mauersberger 
and Nicaud (74), and spread on a pair of CM-leu+dex+CME plates.  Throughout the 
remainder of this thesis, CME was added to liquid and solid media at 20 µg/mL and 
100µg/mL CME, respectively.  After incubation at 28 °C for 4 days, the plates showed a 
total of ~400 colonies.  Of these, 50 transformants were picked and cultured in liquid 
CM-leu+dex+CME at 28 °C, 240 rpm overnight. All cultures grew, with 48 of the tubes 
exhibiting near-saturated growth of the picked culture.  To confirm that this survival was 
due to pCre-AHAS*, four of the cultures were subjected to rapid plasmid recovery 
through an abbreviated version of the method of Hoffman and Winston (75).  The 
recovered DNA was transformed into E. coli under Amp selection and analyzed by 
restriction digest with NcoI (Figures 28 & 33, Table 4).  Excepting a singular band 
attributed to star activity that can be seen brightly in four digests and dimly in two more, 
only one of the analyzed recovered plasmids was found to be inconsistent with pCre-
AHAS*. This demonstrated the link between pCre-AHAS* and resistance to CME at the 
concentrations in use, both on solid and in liquid media. 
Expected Bands  
5635 bp 
1947 bp 
1290 bp 
126 bp 
Table 4: Expected 
bands for NcoI 
digestion of 
recovered plasmids. 
Figure 33: NcoI digests of recovered plasmids.  While the plasmid analyzed in lane 16 produces the 
wrong fragments, the remainder had the correct pattern, occasionally with one star activity band at 3500 
bp. 
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2.2.5.3  Transformation of pCre-AHAS* into ∆FAD2 
The confirmed FAD2 KO Yarrowia strain was cultured and transformed with pCre-
AHAS* according to the method of Mauersberger and Nicaud (74), then spread on CM-
leu+dex+CME plates.  After incubation at 28 °C for 4 days, the pair of spread 
transformant plates showed ~500 colonies. Of these, a total of 50 were picked and 
cultured in liquid CM-leu+dex+CME overnight at 28 °C, 240 rpm.  While thirteen of the 
colonies showed no growth, 20 showed low level and 17 showed extensive growth.  Of 
these, four were analyzed via the same rapid plasmid recovery procedure performed on 
the prototroph (75).  As before, NcoI digests of the recovered plasmids confirmed the 
presence of pCre-AHAS* (data not shown).  All of the colonies that showed growth in 
CM-leu+dex+CME liquid media were replicate streaked in triplicate onto two paired 
plates of YPD+hyg and CM-leu+dex+CME, to test the excision rate of the hph resistance 
cassette (Table 5, Figure 34). 
Table 5:  Loss of hyg resistance vs. incubation time in CM-leu+dex+CME.  Note that, as expected from 
culturing in CM-leu+dex+CME, all streaked colonies retained growth on the solid CME-containing agar.  
++hyg denotes extensive growth on YPD+hyg, while +hyg indicates the presence of a few small colonies. 
After 48 hours incubation, ~96% of streaked colonies did not grow on YPD+hyg, indicating excision of the 
hph resistance cassette by Cre recombinase.  
	  
Three of the colonies that most clearly showed loss of the hph gene (KO2-2, KO5-2, 
KO50-3) were then selected to be grown out and lose pCre-AHAS* plasmid.  Fresh 
stocks of each were cultured overnight and freezer stocks were made in duplicate.  
Incubated for 24 hours in CM-
leu+dex+CME 
 Incubated for 48 hours in CM-
leu+dex+CME 
 
Phenotype Count  Phenotype Count 
++ hyg/ +CME 5  ++ hyg/ +CME 5 
+hyg/ +CME 12  +hyg/ +CME 0 
-hyg/ +CME 97  -hyg/ +CME 109 
-hyg/ -CME 0  -hyg/ -CME 0 
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Figure 34: Pictures of replica plates for hph excision. Plates A & C show growth on YPD+hyg, while B & 
D show growth on CM-leu+dex+CME. The streak in the middle of A is ++hyg, while the isolated colonies 
on plate C were recorded as +hyg. 
2.2.5.4  Grow out for Loss of pCre-AHAS* 
Yeast, like bacteria (76), are capable of losing plasmids containing selection markers  
during extended growth in non-selective media if the plasmid loss confers no benefit to 
its viability without the selection challenge (77-79).  For this project, these conditions 
were provided by culture in YPD.  Initial colonies (KO2-2, KO5-2, KO50-3) were picked 
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from fresh streaks on CM-leu+dex+CME plates incubated overnight at 28 °C.  Each 
colony was inoculated into YPD and incubated overnight at 28 °C, 240 rpm and then it 
was streaked onto CM-leu+dex+CME to test for plasmid loss.  If the cells still grew, an 
aliquot of the YPD culture was reinoculated into fresh YPD and cultured again overnight 
at 28 °C, 240 rpm.  After five cycles of this iterative growth (abbreviated as Gen1, Gen2, 
etc), each of the cultures in Gen3, 4, and 5 were replicate streaked 5 times on YPD and 
CM-leu+dex+CME plates.  After incubation overnight at 28 °C, a total of only three 
colonies from the streaks showed no resistance to Cre-AHAS*.  Freezer stocks of all 
three strains were made in duplicate and stored.  Further investigation to determine the 
reason for this retention of the resistance plasmid concluded that since the AHAS* 
sequence was identical to the AHAS gene present in the gDNA, excessive incubation in 
CM-leu+dex+CME may result in homologous recombination of the mutant gene into the 
genome.  If this were to happen, even upon loss of pCre-AHAS* the colony would retain 
resistance to CME.  As a preventative measure, future transformants were transferred 
directly into YPD for grow outs from the original selection plate, mitigating the 
advantageousness of the recombination event. 
 
2.2.5.5  KO Confirmation via FAME GC/MS Analysis 
As a final confirmation, FAMEs (Fatty Acid Methyl Esters) were prepared from the 
prototroph and cured FAD2 KO Yarrowia strains as previously described (80,81).  Cells 
from each sample were pelleted and then resuspended in 2% H2SO4 in MeOH.  After a 1 
h incubation at 80 °C to produce the methyl esters, the mixture was extracted twice with 
H2O/hexanes, and the organic layers were combined and dried down under a stream of N2.  
The resulting concentrated FAME products were then analyzed by an Agilent 
Technologies GC-MS (7890A GC/ 5975C MS) using a VF-23 column (30 m x 250 µm x 
0.25 µm).  For “VF23FAME”, the oven program was: 60 °C starting temperature,  
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Figure 35: GC traces for FAMEs of Y. lipolytica strains. A shows the prototroph, while B is from FAD2 
KO strains. The peak at 16.00 min is from 18:1∆9, while the peak at 16.80 min is from 18:2∆9,12(See Figure 
36). Note the conspicuous absence of the peak at 16.80 min in plot B, indicating the loss of the ∆12 
desaturase activity from FAD2. 
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Figure 36: Mass spectra of oleic and linoleic acid.  Image A shows the MS for 18:1∆9, while image B shows 
the trace for 18:2∆9,12. Note the smaller MacLafferty peaks at m/z 74, demonstrating the compounds are 
methyl esters. Identification was based on comparison to previous MS spectra of authentic standards (23) 
 
ramp 10 °C/min to 150 °C, hold 5 min; ramp 10 °C/min to 220 °C, hold 1 min; and ramp 
50 °C/min to 250 °C, hold 20 min. The injector was set to 250 °C with He flow rates 
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of 1.9 mL/min.  After running the samples, analysis of the resultant spectra demonstrated 
complete loss of the ∆12-desaturase activity, providing final confirmation of the loss of 
the FAD2 gene (Figure 35, 36).  This concluded the initial studies to demonstrate the 
capability of pCre-AHAS*. 
 
2.3 Results 
The FAD2::hygromycin knockout construct was assembled and transformed into 
prototrophic Y. lipolytica.  The location of this construct was confirmed via PCR 
amplification, and the final strain was cultured for transformation.  The AHAS gene was 
cloned out of Yarrowia and point mutated (W497L) to produce the sulfonyurea herbicide-
resistant mutant AHAS*.  The AHAS* sequence was then inserted into the pDONR221 
donor vector via the BP Clonase reaction. Cre recombinase was transferred from pSH65 
into pY5, then the pY5 LEU2 gene was replaced with Gateway RfA. The final AHAS* 
entry vector and Cre-containing destination vector were combined through the LR 
Clonase reaction to produce pCre-AHAS*, the desired expression vector.  Testing of 
pCre-AHAS* in the Y. lipolytica prototroph strain demonstrated effectiveness of the 
AHAS* gene in providing resistance to the CME herbicide, while transformation into a 
∆FAD2::hph Yarrowia strain confirmed the effectiveness of the Cre recombinase activity 
in excising the hph resistance cassette.  Subsequent iterative growth in nonselective 
media resulted in the loss of pCre-AHAS*, allowing for the knockout of additional genes 
using the loxP flanked hygromycin resistance cassette.  The phenotype of this knockout 
was then reconfirmed through FAMEs analysis via GC/MS.  Both pCre-AHAS* and Y. 
lipolytica ∆FAD2 are complete and functional. 
 
2.4 Discussion 
This chapter details the cloning of AHAS and its mutation to AHAS*, the production 
of the pDONR-AHAS* entry vector, the transfer of Cre recombinase to pY5 and 
subsequent insertion of the RfA gateway, the final production of pCre-AHAS*, and its 
testing on the Yarrowia ∆FAD2::hph strain.  Surprisingly, the majority of difficulties in 
completion of the pY5-Cre Gateway destination vector came from improper digestion.  
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Despite possessing the proper sequence (confirmed through cycle sequencing), digests 
with single enzymes, and even the mutagenic insertion of a second SphI site, the 
anticipated band for excision and ligation constituted a comparatively small fraction of 
the double restriction digest products.  This aberrant digestion pattern was maintained 
independent of enzyme concentration, substrate concentration, incubation time, buffer, 
and across a number of tested buffer concentrations.  Whether this is an artifact as a result 
of the structure of the specific DNA sequence being digested or Star activity from EcoRI, 
SphI, or both (82) is unclear.  However, since the aberrant digests occurred even with low 
enzyme concentration, low enzyme to DNA ratio, short digestion time, optimal buffers 
(listed as 100% activity per NEB), and Mg2+ as the divalent cation concurrently, Star 
activity is unlikely. 
Excepting this singular aberration, integration of the Cre-AHAS* system for use in 
our lab was seamless.  Excision of the hph resistance cassette by Cre recombinase was 
highly efficient, with ~86% showing excision after 24 hours incubation time, and ~96% 
showing excision after 48 hours incubation.  In addition, selection in liquid cultures by 
CME was extremely effective, with cell death seen for all [CME] ≥ 5µg/mL. Growth on 
solid media was more challenging because the effective concentration approached the 
maximum solubility of CME in the media.  Regardless, every step of the selection 
process had high specificity and high efficiency.  pCre-AHAS* is a specialized plasmid 
for single resistance serial gene knockout, showing excellent results (See also Chapter 3 
for POX gene knockouts).   
While the core idea of Cre-lox resistance excision stems from Fickers et al. (54), 
previous studies have not implemented the secondary resistance of AHAS* as a selection 
factor.  A number of these studies focus on using metabolic auxotroph strains, such as 
Yarrowia ∆LEU or ∆URA phenotypes, and then transforming with the pCre that also 
contains the complementary amino acid synthesis gene, allowing growth on CM 
knockout media.  While this previous system is effective, use of pCre-AHAS* requires 
no alterations to the original metabolic genotype.  The only mutations required are those 
implemented through the hygromycin-based knockout constructs, and the final resulting 
strain contains a minimal residual DNA scar from the replacement of the knocked-out 
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gene with an inactive loxP site. In addition to this, CME is an excellent selection marker 
in liquid media and acceptable selection marker on solid media for Yarrowia lipolytica 
However, since CME is effective against a wide range of lifeforms (plants, fungi, bacteria, 
and algae), yet shows little to no toxicity against higher organisms like fish and mammals, 
this modified system may be transferred for use in a wide range of organisms. Since its 
discovery, Cre recombinase has been implemented for gene excision and insertion in a 
number of organisms, ranging from knockout mice (83), to plants like bananas (84), rice 
(85), and rapeseed (86), bacteria like Coxiella burnetii (87), and yeasts like Yarrowia.  So 
long as the organism in question contains a characterized AHAS gene with a known 
resistance mutation for sulfonylurea herbicides, use of this alternate Cre-AHAS* system 
may be easily implemented for the organism with minimal alteration from the methods 
described in this thesis.  The only notable difference is that Cre recombinase and the 
Gateway must be implemented into an organism specific plasmid, with appropriate origin 
of replication, promoter, terminator, etc.  Should these conditions be satisfied, this 
effective system may be generalized for research and industrial use. 
While the current results are very positive, this final pCre-AHAS* may be improved 
through a number of additional mutations to the AHAS* gene which leave its function 
and activity unaltered.  Since the potential for integration of the AHAS* gene is nonzero, 
and increased by the length of incubation in selective media, additional alterations which 
do not affect its effectiveness but might reduce this eventuality’s likeliness are desirable.  
Implementation would likely be dependent on the utility of the plasmid to the scientific 
community at large.  
In short, this chapter demonstrates the production of a Cre-lox recombinase system in 
novel conjunction with the AHAS* CME-resistant mutant gene, its assembly via the 
Gateway® cloning system, and its testing on a ∆FAD2::hph Yarrowia knockout strain. 
Testing demonstrates high specificity, high efficiency, and excellent selection.   
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2.5  Future Uses 
 
2.5.1  Epa955 and Epa2161 
A number of acetylenases have been previously characterized, including the landmark 
study of Crep1 (18), the first ∆12-acetylenase ever cloned and functionally characterized. 
More recent studies have identified new plant acetylenases and expanded the range into 
fungal acetylenases (16), moss acetylenases (88), and even acetylenases from moths (89). 
Many of these characterized acetylenases contain multifunctional activities, such as the 
∆12 cis and trans desaturation activity of Crep1 (90), the ∆11 desaturase/acetylenase 
activity and ∆13 desaturase activity from Thaumetopoea pityocampa (89), and the ∆6 
desaturase/acetylenase activity from Ceratodon purpureus (88). Despite the presence of 
∆14-desaturation activity on 18:1∆9,12a fatty acid products in CfACET Yarrowia 
expression clones, no other ∆14-desaturation products were observed (unpublished 
research) (16).  Similar results are seen with the ∆13 desaturase activity of Tpi-PGFAD 
(89), as well as many others.  This secondary activity is proposed to be a result of the 
insertion of the short alkyne bond, allowing access of the to-be conjugated position to the 
original desaturase active site (89,91,92).  However, in most cases this desaturation and 
the original desaturation step may be attributed to endogenous FAD2 or potentially FAD3 
activities instead of the acetylenase.  Acetylenic natural products are derived from three 
major biosynthetic pathways: the crepenynic acid pathway, the stearolic acid pathway, 
and the tariric acid pathway.  These pathways differ based on the regioselectivity of the 
desaturation/acetylenation of the oleic acid precursor, producing crepenynic acid 
(18:1∆9,12a), stearolic acid (18:0∆9a), and tariric acid (18:0∆6a), respectively.  The vast 
majority of acetylenic metabolites are produced via the crepenynic acid pathway (seen in 
part in Figure 4, and in full in Figure 37).  A recent study by the Minto lab has resulted in 
the cloning and characterization of two enzymes involved in the crepenynic acid pathway, 
named Epa955 and Epa2161 (23).  A TBlastX search of the publically available E.  
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Figure 37: The crepenynic acid pathway, as originally proposed by Bu'Lock (24) 
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purpurea transcriptome against the sequences of 48 known and putative acetylenases and 
diverged desaturases resulted in the identification of these two ∆12-acetylenase homologs.  
After confirmation of the ORF via RACE (Rapid Amplification of cDNA Ends) 
amplification, the full-length targets were synthesized in four codon-optimized; Epa955 
RACE opt 2 (Epa955R2), Epa955 RACE opt 3 (Epa955R3), Epa955 trans opt (Epa955T), 
and Epa2161 trans opt (Epa2161T) and expressed in Y. lipolytica.  Products were 
adjusted to the consensus RACE transcripts (RACE opt) or the transcriptomic sequence 
(trans opt).  Characterization of the activities of both enzymes in Yarrowia (ATCC 
76982) demonstrated production of crepenynate from linoleic acid via a ∆12 acetylenase 
activity.  These cultures also 
produced of dehydrocrepenynate, 
indicating a ∆14 desaturase activity.  
While this may be consistent with 
both of these enzymes being in fact 
bifunctional ∆12 
desaturases/acetylenases, the 
Yarrowia strain used contained a 
FAD2 ∆12-desaturase that could 
have been the source of this “∆14 
desaturase” activity.  With the 
production of the Yarrowia ∆FAD2 
knockout, a reinvestigation of this 
potential secondary activity has now 
become possible.  Future work will 
seek to characterize whether Epa955 
and Epa2161 do indeed possess a ∆12- and/or ∆14-desaturase activities. 
 
2.5.2  Lipid Degradation 
 While chapter three deals with the initial work of a study on lipid degradation in 
∆POX2 Yarrowia strains, a number of other knockouts are of interest.  Since effective 
Figure 38: Epa955 plasmid map. 
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production of lipids for biodiesel requires optimization for superior fuels, understanding 
the mechanism present for degradation and alteration is key in tailoring the product lipid 
pool.  Initial studies have marked out 18:1∆9 as a product of interest with good fit for 
viscosity, cold flow, oxidative stability, and lubricity, maintaining many of the key 
qualities seen in current fuels (93).  Ergo, knockouts that amplify the amount of this 
product in the stored lipid are desirable.  The specific activities of POX4 and POX5, if 
any, remain unknown.  The effects of knockouts at distinct points during lipid 
degradation (MFE1, POT1) on the lipid profile remain uninvestigated.  Many previous 
studies in Yarrowia seek to maximize total lipid output, rather than examine the lipid 
profile in detail.  The system developed here allows for this examination without the 
presence of any metabolic mutations with excellent selection. 
 
2.5.3 Gene Knock-Ins with pCre-AHAS* 
Simple modifications to the knockout constructs in use allow for the easy insertion of 
exogenous genes in place of those knocked out within the genome.  By inserting the gene 
sequence within the construct but outside of the mutant loxP sites, selection using the hph 
marker and excision of this resistance via the method previously descried is unaltered 
(see Figure 39).  Instead of leaving only the loxLR scar in the DNA, the gene is now 
replaced by the knock-in, allowing this inserted gene to use the promoter, terminator, and 
other metabolic machinery already in place.  While assembly of a test knock-in construct 
was initiated, final testing of the product was not yet completed.  Should the test be 
successful, the pCre-AHAS* methodology will provide an efficient means for both 
deletion and insertion of chosen genes and the biochemical characterization of metabolic 
pathways. 
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Figure 39. Gene knock-in construct diagram. 
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CHAPTER 3.  LIPID UPTAKE AND DEGRADATION IN POX KO STRAINS 
 
 
 
3.1  Background 
 
While the general mechanisms for the degradation of lipids by Yarrowia are 
reasonably well understood, a number of open questions still remain.  Several researchers 
have investigated the uptake of common lipids by Yarrowia, such as 18:1∆9, 18:2∆9,12, and 
18:3∆9,12,15 (94,95) but little to no research has been performed on the uptake of less 
common lipids, the effects of the degrees of unsaturation on lipid accumulation, and the 
selectivity of the exogenous fatty acid uptake.  This same exploration of selectivity 
extends throughout the lipid degradation.  Past research showed the specificity for POX2 
and POX3 oxidases (48-50) for medium and short fatty acid chains, respectively, while 
recent research has shown POX1 and POX6 preferentially degrade dicarboxylic acids.  
To date, POX4 and POX5 are reported as having nonspecific binding across saturated 
FAs between C4 and C16 (51,52); however, a recent study looking at the viability of PHA 
production demonstrated a high activity of POX5 against the odd chain MUFA 17:1∆10 
(32).  While of great use in the general determination of the activity of relevant POX 
genes, these studies lack an assessment of a number of relevant topics. None of the 
activity studies cited here look at any desaturated compounds (excepting the PHA study 
which looked at three).  As such, none look at the importance of alkene stereochemistry, 
the preferential degradation or integration of desaturated lipids, or activities against 
mixed substrates which are not dominantly even-chain saturated FAs (such as stearin and 
other animal fats).  This chapter seeks to rectify this information void with a preliminary 
analysis of lipid uptake and degradation in the Yarrowia prototroph and POX knockouts. 
To properly analyze the lipid content for the purposes of this study, a method is 
required that allows for quantitation of the lipid present in the cells not only after growth, 
but of that which remains in the media and which has not been taken up by the cell.  This 
54 
 
is complicated by the presence of the detergent NP-40 in the growth media.  While 
exogenously fed free lipids may be easily taken up, growth above a characteristic 
concentration of lipid results in the formation of micelles, limiting the availability of the 
lipid to the cells.  To mitigate this difficulty, a small amount of detergent is added, which 
prevents the formation of these lipid-lipid interactions. However, when this NP-40-
containing media is mixed with hexanes, the result is a heterogenous emulsion.  No 
hexane may be successfully recovered.  In addition, the procedure must be highly 
efficient to process the number of product fatty acid profiles necessary for the analysis. 
The resulting protocol is detailed in Figure 39.  
 
3.2 Materials and Methods 
 
3.2.1 Preparation and Setup 
To find a useful concentration of NP-40 that did not result in an emulsion, hexane 
extraction was tested across a range of reasonable NP-40 concentrations. Since the 
critical micelle concentration for NP-40 was reported by the manufacturer as 0.0232% 
(w/v) (96), the sample was tested by serial dilutions of the stock 1% NP-40 solution. 
Concentrated 50 mM stocks were made of each fatty acid for feeding, with the FAs 
dissolved in DMSO.  To determine the retention time of each of the fed lipids, about 10 
µL of each stock solution was prepped and converted into FAMEs, which were then 
analyzed by GC/MS. To quantitate the amount of lipid taken up by the cell, 11-Br 11:0 
was added to each sample prior to the preparation of FAMEs. 
 
3.2.2 Prototroph 
As previously stated, the prototrophic Yarrowia strain grows with 85-90% of the total 
lipid content comprised of five fatty acids: 16:0, 16:1∆9, 18:0, 18:1∆9, and 18:2∆9,12 (31). 
While this fact remains unchanged regardless of the identity of any of the lipids fed in 
this experiment, the ratios of these key lipids shift in response to the identity of the 
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Culturing of cels with and w/o feeding 
Cels are peleted, then washed twice with 0.1% 
NP-40 and twice with water 
The cels are spiked with bromoacid and are 
prepared with 2% sulfuric acid in MeOH 
FAMEs are extracted twice with hexanes 
FAMEs are dried down under N2, then 
redissolved in hexanes 
Analyzed via GC-MS 
The media and washes are diluted to 0.025% 
NP-40, and spiked with the bromoacid 
Extracted twice with 3-4 mL hexanes, then dried 
down under N2 
Redissolved with 2% sulfuric acid in MeOH, 
then heated to make FAMEs 
Extracted twice with 2-3 mL hexanes, then dried 
down under N2 and redissolved in hexanes 
Analyzed	  by	  GC-­‐MS	  
Figure 40: Separation and preparation scheme for prototroph/∆POX strains, with feeding. 
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lipids that have been exogenously fed.  Cultures were prepared using 3 mL of YPD+0.1% 
NP-40 inoculated with 30 µL of freshly cultured cells and 30 µL of the appropriate ~50 
mM FA solution stock.  The resulting culture tubes were incubated 24 hours at 28 °C, 240 
rpm and FAMEs were prepared using 250 µL of the final grown culture according to the 
method described in Figure 39.   Once complete, these FAME spectra were tabulated and 
analyzed via statistical analysis for determination of relevant results.  
 
3.2.3 POX2 Knockout Strain 
The ∆POX2 knockout construct was produced by Dr. Brenda Blacklock and 
transformed by her into the Yarrowia prototroph. Streaks of the positive transformants 
were made on YPD+hyg, and given to me for use. The positioning of the ∆POX2 
construct was verified through PCR amplification, then the sample was cultured and 
prepared in the fashion as the prototroph. 
 
3.3  Results 
 
3.3.1 Stocks, Sample Spectra, and Preparatory Work 
 
Table 6: Stock solutions of fatty acids.  Each FA was dissolved in DMSO, then stored at -80 °C to limit air 
oxidation. 
Identity Stock concentration 
(mmol/L) 
Retention Time 
(min) 
11:1∆10 51.6 7.33 min 
15:1∆10 53.3 11.05 min 
17:1∆10 51.8 14.23 min 
17:1∆10t 51.8 13.94 min 
19:1∆7 49.6 16.94 min 
19:1∆10 48.1 16.98 min 
19:1∆10t 49.6 16.83 min 
14:1∆9 53.9 9.86 min 
14:1∆9t 53.9 9.70 min 
16:1∆9 50.3 12.31 min 
16:1∆9t 51.1 12.09 min 
18:2∆9,12 53.3 16.56 min 
18:3∆9,12,15  (α) 51.4 17.41 min 
18:3∆6,9,12  (γ) 51.4 17.05 min 
11-Br 11:0 51.1 16.00 min 
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The actual stock FA solution concentrations may be seen in Table 6, along with the 
retention times for the FAME of each lipid.  When working to find an internal standard, 
initial attempts with 9:0 and 13:0 were fruitless, since the lipids evaporated completely 
out of solution prior to analysis. Clearly, neither of these two options would be useful 
through two separate drying steps in quantitation of the lipid in the wash solution.  
Instead, 11-Br-11:0 was selected.  Not only did it occupy an open space in the normal 
lipid profile, falling between 18:1∆9 (15.73 min) and 18:2∆9,12 (16.56 min), but it showed 
minimal degradation, minimal evaporation, and excellent quantitation (Figure 45).   
The acquisition of the feeding data was most hindered by the colloid formation 
caused by the presence of NP-40.  Since initial trial cases using the traditional 1% NP-40 
for washes and YPD+1% NP-40 for feeding resulted in the formation of a heterogeneous 
sludge-like colloid upon addition of hexanes, the extraction was tested across a range of 
reasonable NP-40 concentrations.  The emulsion was seen for all wash mixtures with 
concentrations of NP-40 greater than 0.025%, a value extremely close to the critical 
micelle concentration of 0.0232%.  While using a higher concentration would ensure the 
prevention of micelle formation, the increasing NP-40 concentration would require 
substantial dilution of the washes for subsequent extraction.  To compensate for this, the 
media and wash solution were made with 0.1% NP-40 and then diluted later as necessary, 
resulting in a final 3 mL of the wash solution.  This volume could be extracted with 3 mL 
hexanes without overfilling the FAMEs tubes used while still maintaining an acceptable 
mass balance for useful extraction.  
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3.3.2 Prototroph 
 
3.3.2.1  Lipid Uptake, Incorporation, and Degradation 
 While previous studies have investigated preferential degradation of certain lipids in 
natural mixtures (animal fats, plant oils, etc.), this study looks at the feeding of singular 
lipids. The generalized results of the feeding may be seen in table 7.  
 
Figure 41: Prototroph Yarrowia FAMEs spectrum with 11-Br-11:0 added as an internal standard. 
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Equation 1: Equation set for the calculated values seen in Table 7. 𝐸𝑥𝑜𝑔𝑒𝑛𝑜𝑢𝑠𝑙𝑦  𝑓𝑒𝑑  𝑙𝑖𝑝𝑖𝑑   = 𝐹𝐴  𝑠𝑡𝑜𝑐𝑘 ∗ 30  µμ𝐿3.0  𝑚𝐿  𝑚𝑒𝑑𝑖𝑎 ∗ 0.25  𝑚𝐿  𝑚𝑒𝑑𝑖𝑎  ℎ𝑎𝑟𝑣𝑒𝑠𝑡𝑒𝑑 
 𝐼𝑚𝑝𝑜𝑟𝑡𝑒𝑑  𝑒𝑥𝑜𝑔𝑒𝑛𝑜𝑢𝑠  𝑙𝑖𝑝𝑖𝑑 = 𝐸𝑥𝑜𝑔𝑒𝑛𝑜𝑢𝑠𝑙𝑦  𝑓𝑒𝑑  𝑙𝑖𝑝𝑖𝑑 − µμ𝑚𝑜𝑙  𝑙𝑖𝑝𝑖𝑑  𝑖𝑛  𝑤𝑎𝑠ℎ 
 𝐿𝑖𝑝𝑖𝑑  𝑎𝑐𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑒𝑑 = 𝐹𝑒𝑒𝑑𝑖𝑛𝑔  𝑚𝑜𝑙  𝑜𝑓  𝐹𝐴 − 𝑃𝑟𝑜𝑡𝑜𝑡𝑟𝑜𝑝ℎ  𝑚𝑜𝑙  𝑜𝑓  𝐹𝐴 
 𝐿𝑖𝑝𝑖𝑑  𝑎𝑐𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑒𝑑 = 𝐹𝑒𝑒𝑑𝑖𝑛𝑔  𝑚𝑜𝑙  𝑜𝑓  𝐹𝐴 − 𝑃𝑟𝑜𝑡𝑜𝑡𝑟𝑜𝑝ℎ  𝑚𝑜𝑙  𝑜𝑓  𝐹𝐴𝐸𝑥𝑜𝑔𝑒𝑛𝑜𝑢𝑠𝑙𝑦  𝑓𝑒𝑑  𝑙𝑖𝑝𝑖𝑑 ∗ 100% 
 𝐷𝑒𝑔𝑟𝑎𝑑𝑒𝑑  𝑓𝑒𝑑  𝑙𝑖𝑝𝑖𝑑 = 𝐼𝑚𝑝𝑜𝑟𝑡𝑒𝑑  𝑒𝑥𝑜𝑔𝑒𝑛𝑜𝑢𝑠  𝑙𝑖𝑝𝑖𝑑 − 𝐿𝑖𝑝𝑖𝑑  𝑎𝑐𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑒𝑑 
 
 
Despite an incubation time of only one day in rich media, the majority of the lipids 
exogenously fed in each trial were taken up by the Yarrowia prototroph strain.   Of the 
results found, only 15:1∆10 had a high standard deviation, with all other µmol results 
accurate to the fourth decimal place.  The results seen for lipid uptake do not indicate a 
selectivity based on chain length, lipid desaturation, or configuration of the double bonds 
among the FAs studied.  Accumulation of the fed lipid in the prototroph heavily favors 
the LCFAs studied, with greatest accumulation seen for 16:1∆9, 18:2∆9,12, 18:3∆9,12,15, 
18:3∆6,9,12,  and 17:1∆10.  Due to the variability in the values measured, no significant 
alteration is seen for 11:1∆10, 14:1∆9t, 14:1∆9, or 15:1∆10, indicating the degradation of all 
of the exogenous lipid which was taken up by the cells.   Every one of the lipids of size 
C16 or greater with a ∆9 alkene bond show accumulation in excess of 7%, implying that 
this bond may enhance accumulation rates.  The cis alkene configuration is favored for 
accumulation in 16:1∆9 and 17:1∆10, while the larger 19:1∆10 and smaller 14:1∆9 show 
minimal difference between the isomers.  
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Table 7: Lipid feedings of prototroph, with quantified uptake, incorporation, and degradation. While the 
first four fed lipids showed accumulation within the standard deviation of their values (an insignificant 
change), the remainder all accumulated significantly. 
 
3.3.2.2  Lipid Profiles 
The results for the overall lipid profiles may be seen in Table 8.  A number of 
interesting alterations present themselves upon close inspection.  Accumulation of 11:1∆10 
is relatively uniform across all the feedings performed.  However, 15:1∆10 shows  
Lipid 
uptake 
Exogenously 
fed lipid 
(µmol) 
Imported  
exogenous 
lipid  
(µmol) 
Lipid 
accumulated 
(µmol) 
Lipid 
Accumulated 
(%) 
Degraded 
fed lipid 
(µmol) 
11:1∆10 0.129 0.126 trace -0.33 0.127 
14:1∆9 
0.135 0.134 0.001 0.39 0.133 
14:1∆9t 0.135 0.133 0.001 0.89 0.132 
15:1∆10 0.133 0.129 0.004 3.0 0.125 
16:1∆9t 0.128 0.126 0.009 7.1 0.117 
16:1∆9 0.126 0.124 0.046 36.3 0.078 
17:1∆10t 0.129 0.129 0.011 8.7 0.118 
17:1∆10 0.129 0.129 0.018 13.8 0.112 
18:2∆9,12 0.133 0.131 0.015 11.5 0.116 
18:3∆9,12,15  
(α) 0.128 0.125 0.039 30.5 0.086 
18:3∆6,9,12  
(γ) 0.128 0.127 0.027 21.2 0.100 
19:1∆7 0.124 0.124 0.004 3.1 0.120 
19:1∆10 0.120 0.120 0.004 3.0 0.116 
19:1∆10t 0.124 0.124 0.004 2.9 0.120 
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increased accumulation with the feedings of 17:1∆10 and 19:1∆10, both with the cis and 
trans isomers.  Also, 17:1∆10 shows accumulation from feeding with 19:1∆10. This 
increasing accumulation could be due to β-oxidation of the FA acyl chain with 
isomerization of the double bond, or it could be a result of omega-oxidation, as seen in 
yeasts such as Candida cloacae (97).  Feedings with α-18:3 resulted in decreased 
accumulation for all lipids studied, including most notably a decrease of nearly 50% in 
the amount of accumulated 18:2∆9,12.  Feedings with γ-18:3, however, resulted in 
increased accumulation for all lipids studied excepting 18:2∆9,12, which showed ~30% 
decrease in accumulation.  Feedings with 14:1∆9 resulted in a lipid profile very similar to 
the prototroph, while feedings with 14:1∆9t showed an increase in lipid accumulation 
across those investigated. Feeding 16:1∆9 resulted in enrichment of only 16:1∆9 and 18:1∆9, 
implying the action of an elongase, while feeding 16:1∆9t resulted only in enrichment of 
the 16:1∆9t lipid.  This indicates that the enrichment seen with 14:1∆9t is not exclusively 
caused by the stereochemistry, but is specific to that compound for unknown reasons.  
 
3.3.3  ∆POX2 Strain  
As shown in Table 9, the Yarrowia ∆POX2 mutant deviates from the prototrophic 
strain in several key ways.  The most notable and obvious difference is that the amount of 
accumulated lipid has increased dramatically, with increases of between 20-50% for 16:0, 
16:1∆9, 16:1∆9t, 18:1∆9, and 18:2∆9,12, and a decrease of ~40% for 18:0.  While not 
unexpected due to the double nature of POX2 as a regulatory factor in the assembly of the 
POX complex and as a medium-chain oxidase, the increased accumulation is strikingly.  
This increase in lipid accumulation is relatively uniform across all of the ∆POX2 feedings.  
Similar to the prototroph, feedings with α-18:3 resulted in decreased accumulation for 
all lipids studied, including most notably a decrease of nearly 25% in the amount of 
accumulated 18:2∆9,12.  Unlike in the prototroph, feedings with γ-18:3 also resulted in 
decreased accumulation for the lipids studied.  The ∆POX2 15:1∆10 no longer shows 
increased accumulation with the feedings of 17:1∆10 and 19:1∆10, with either the cis or 
trans isomers.  This implies the loss of the enzyme aiding in this conversion, supporting 
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the idea that this accumulation in the prototroph could be due to β-oxidation of the FA 
acyl chain by POX2, followed by isomerization of the double bond.  
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3.4  Discussion 
 While the information contained here is new, it is by no means complete.  Our 
preliminary data set encompasses the prototroph and one of the six POX genes, leaving 
the remaining five for completion.  As of this time, verified constructs exist for all 6 of 
the POX genes with verified transformants of POX2, POX3, and POX4.  While not 
completed in time for inclusion within this thesis, it is our intention to complete analysis 
of all six POX genes.  The main limiting factor is the sizable time commitment to be able 
to complete each data set and analyze the results.  While the method shown in Figure 44 
was the most efficient sequence to produce the FAMEs of both the cells and wash 
solution, it is worth noting that preparation of large sets of feedings rapidly increases the 
time scale to complete the method.  For reference, the completion of a set of 48 feedings 
required 2-3 days of exclusive attention to complete, with approximately 21.5-22 hours to 
acquire each set of GC/MS results from the FAMEs samples.  This problem is a tractable 
one, but one that will require far more time invested.  Of the remaining genes to 
investigate, the one of most interest is POX5.  Previous studies have shown it had a 
demonstrable and specific activity against 17:1∆10 , indicating the possibility of a specific 
activity, perhaps against desaturated FAs.  Until the data is collected and analyzed, 
however, this remains speculation. 
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CHAPTER 4.  MATERIALS AND METHODS 
 
 
4.1  Materials 
 Yeast and E. coli media components (peptone, tryptone, yeast extract, yeast 
nitrogenous base, agar) were manufactured by Becton Dickinson & Co. (Franklin Lakes, 
NJ).  Tris base, PEG4000, Tergitol NP-40, lysozyme, DMSO, and all amino acids used 
for CM dropout powder were purchased from Sigma-Aldrich (St. Louis, MO).  Dextrose, 
NaCl, NaOH, agarose, sodium acetate, EDTA, lithium acetate, and ammonium sulfate 
were all purchased from Fisher Scientific or ACROS Organic (Fair Lawn, NJ).  For the 
fatty acid feedings, 9:0, 13:0, and 11-Br-11:0 were all purchased from Sigma-Aldrich (St. 
Louis, MO), while the remainder were purchased from Nu-Chek-Prep (Elysian, MN).  
All restriction enzymes and buffers were purchased from New England Biolabs (Ipswich, 
MA).  All primers were obtained from Integrated DNA Technologies (Coralville, IA) and 
synthetic genes were purchased from Genscript (Piscataway, NJ).  The pSH65 plasmid, 
containing the Cre recombinase gene, was graciously provided by Prof. Mark Goebl of 
the IU School of Medicine, Indianapolis, IN.  The pY5 plasmid was graciously provided 
by E. Cahoon from the University of Nebraska, Lincoln, NE. All the materials for the 
Gateway® reactions, including pDONR, Gateway RfA, and all associated buffers and 
reaction mixes and the 1-kb ladder were obtained from Invitrogen (Grand Island, NY).  
Chlorsulfuron (98%) and chlorimuron ethyl (95%) were both purchased from AK 
Scientific, Inc. (Mountain View, CA).  The Wizard® Plus SV Minipreps DNA 
Purification System for plasmid purification was purchased from Promega (Madison, WI). 
Terminator cycle sequencing was performed using the BigDye® Direct Cycle 
Sequencing Kit from Invitrogen, through Life Technologies (Grand Island, NY). PCR 
mutagenesis was performed using the Quikchange II Site Directed Mutagenesis kit from 
Agilent (Santa Clara, CA).  DNA amplification was performed using the GoTaq® DNA 
Polymerase kit from Promega.  A QIAEX II DNA Extraction Kit was purchased from 
QIAGEN (Germantown, MD).  
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4.2  Instrumentation 
DNA concentration was measured using a Thermo Scientific Nanodrop 2000 
spectrophotometer using 1 µL of the plasmid DNA dissolved in TE.  All PCR reactions 
were performed on a Eppendorf Mastercycler Gradient thermocycle.  Cell counting was 
performed using a Nikon Eclipse TS100 Confocal microscope with visual counting on a 
Hausser Scientific Bright-line hemacytometer.  A Glenmills Inc. Mini Beadbeater was 
used to lyse yeast cells, while centrifugation was performed with a IEC HN-SII high 
speed centrifuge and Eppendorf 5415R microcentrifuge.  Absorbance readings for cell 
growth were taken using a Thermo Scientific Genesys 10 UV/Vis spectrophotometer.  
All GCMS spectra were taken using an Agilent Technologies GC (7890A) and MS 
(5979C), with the samples run through a VF23 30 m X 0.39 mm X 0.25 µm GC column.  
All FAMEs were run using the program VF23FAME: 60 °C starting temperature, ramp 
10 °C/min to 150 °C, hold 5 min; ramp 10 °C/min to 220 °C, hold 1 min; ramp 50 °C/min 
to 250 °C, hold 2 min. 
 
4.3  Media 
 
4.3.1 LB 
When making liquid media, approximately 200 mL of Millipure-filtered 
microbiology grade water was added with a magnetic stirbar to a 500-mL graduated 
cylinder. To this was added 5 g tryptone, 2.5 g yeast extract, and 5.0 g NaCl. The 
graduated cylinder was filled to the 500-mL line, and allowed to mix thoroughly on a 
stirring plate.  The media was transferred to a screw-top bottle and then autoclaved for 15 
min at 15 psig (121 °C).  After cooling, the media was stored for use.  If an antibiotic was 
required (e.g., Amp, Kan), it was added individually to each culture prior to inoculation.  
When making solid agar plates, 500 mL of Millipure-filtered microbiology grade 
water was measured using a 500-mL graduated cylinder and then approximately half of it 
was added to a 1-L flask.  To this, 5 g tryptone, 2.5 g yeast extract, 5.0 g NaCl, and one 
NaOH pellet were added with stirring.  The remainder of the water was added, the 
solution was transferred to a flask, 10 g of agar were added, and mixed briefly in the 
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solution.  The flask was capped with an aluminum foil sheath and autoclaved for 15 min 
at 15 psig.  After autoclaving, the media was allowed to slowly cool with stirring on the 
magnetic stir plate.  If an antibiotic was needed, the appropriate amount (500 µl of a 
1000x premade stock) was added after the flask was cool enough to lightly touch by hand 
(~60-70 °C).  After mixing, the media was poured in a series of plates, and allowed to 
cool and dry on the benchtop overnight. The next morning the plates were bagged, and 
stored in the 4 °C fridge. 
 
4.3.2 YPD 
When making liquid media, 5 g yeast extract, 10 g peptone, and 10 g dextrose were 
added to 500-mL graduated cylinder, and water was added to the 500 mL line. The media 
was mixed, bottled, and autoclaved 15 minutes at 15 psig in the same fashion as for LB. 
After cooling, the media was stored for use. If liquid media required the addition of an 
antibiotic (e.g. hyg), it was added individually to each culture prior to inoculation.  
 When making solid agar plates, 5 g yeast extract, 10 g peptone, 10 g dextrose, one NaOH 
pellet, and 10 g agar were added to a 1-L flask with 500 mL of water and mixed 
thoroughly. The flask was capped with an aluminum foil sheath and autoclaved 15 
minutes at 15 psig.  After autoclaving, the media was allowed to slowly cool with stirring 
on the magnetic stir plate.  If hyg was needed, 667 µL of the 300 mg/mL hygromycin 
stock was added after the flask was cool enough to lightly touch by hand (~60-70 °C).  
After mixing, the media was poured in a series of plates, and allowed to cool and dry on 
the benchtop overnight. The next morning the plates were bagged, and stored in the 4 °C 
fridge. 
 
4.3.3 CM-leu+dex 
When making liquid media, 1.30 g CM–leu dropout powder, 1.70 g yeast nitrogenous 
base (-amino acids, -ammonium sulfate), and 5.0 g ammonium sulfate were added to 1-L 
graduated cylinder.  The graduated cylinder was filled with water to the 900-mL line, and 
allowed to mix thoroughly.  After the media was well mixed, it was poured into an 
appropriate bottle, labeled, and autoclaved.  After cooling, the media was stored for use.  
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To minimize issues with storage, 20% (w/v) dex solution was produced separately and 
stored.  Before use, an appropriate volume of CM-leu media was mixed with 1/9 of its 
volume in 20% dex solution, and, if needed, CME from an acetone or ethanol stock to 20 
µg/mL.  The final media was mixed thoroughly then dispensed to each culture tube/flask. 
When making solid agar plates, 0.65 g CM–leu dropout powder, 0.85 g yeast 
nitrogenous base (-amino acids, -ammonium sulfate), 2.5 g ammonium sulfate, one 
NaOH pellet, 50 mL of 20% (w/v) dextrose solution, 10 g agar, and 450 mL of water 
were added to a 1-L flask with stirring.  The flask was capped with an aluminum foil 
sheath and autoclaved.  After autoclaving, the media was allowed to slowly cool with 
stirring on the magnetic stir plate.  If CME was needed, it was added from an acetone or 
ethanol stock to 100 µg/mL after the flask was cool enough to lightly touch without 
burning (~60-70 °C).  After mixing, the media was poured in a series of plates, and 
allowed to cool and dry on the benchtop overnight. The next morning the plates were 
bagged, and stored in the 4 °C fridge. 
 
4.3.3.1  CM Dropout Powder 
To produce CM knockout powder, all of the nutrients in Table 10 were mixed 
together in the masses specified, excepting the nutrient(s) specified as the dropout.  For 
CM-leu, appropriate masses of all the listed nutrients except L-leucine were mixed 
together and ground together by pestle in a mortar until smooth and homogenous. The 
resulting knockout powder was stored in an airtight jar.   
 
4.3.3.2  20% (w/v) Dextrose Solution  
Dextrose solution was produced in 50-mL portions for ease of use.  Dextrose (10g) 
was massed and then added to a sterile 50-mL Falcon tube.  Millipure microbiology 
grade water was added to about the 45-mL line and the dextrose was dissolved by 
repeated agitation of the Falcon tube.  Once the dextrose was fully dissolved, the tube 
was filled to the 50-mL line with Millipure water and shaken to mix.  The mixture was 
sterilized by syringe-driven Millipore filtration into a second sterile 50-mL Falcon tube, 
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then stored on the bench top.  Two 50-mL tubes were made for each batch of liquid CM-
leu+dex media, while one was made for each run of plates. 
 
Table 10: CM Dropout Powder Recipe showing all possible components. 
 
 
  
 Nutrient Amount in dropout 
powder (g) 
Final concentration in 
prepared media (µg/mL) 
Adenine (hemisulfate salt) 2.5 40 
L-Arginine (HCl) 1.2 20 
L-Aspartic acid 6.0 100 
L-Glutamic acid (free acid) 5.21 100 
L-Histidine 1.2 20 
L-Leucine 3.6 60 
L-Lysine (mono-HCl) 1.8 30 
L-Methionine 1.2 20 
L-Phenylalanine 3.0 50 
L-Serine 22.5 375 
L-Threonine 12.0 200 
L-Tryptophan 2.4 40 
L-Tyrosine 1.8 30 
L-Valine 9.0 150 
Uracil 1.2 20 
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4.4  General Methods 
 
4.4.1 DNA Preparation 
 
4.4.1.1  Rapid NaOH Yarrowia gDNA Prep 
The method in use is similar to that described by Wang et al. (73). A small amount of 
cells from a single colony on a fresh YPD agar plate grown overnight, approximately 
enough to cover the very end of a 200 µL micropipette tip, was added to a PCR tube with 
10 µL of 20 mM NaOH.  The tube was then incubated for 15 min at 99 °C on an 
Eppendorf Mastercycler gradient thermocycle, and spun down at ~ 3k rpm on a 
microcentrifuge for approximately 30 sec.  The resulting aqueous layer over the pelleted 
cell debris contained Yarrowia gDNA, and was used directly for PCR amplifications 
without purification. 
 
4.4.1.2  Wizard® Plus Minipreps Plasmid DNA Prep 
This system, available as a kit from Promega, is used for the rapid acquiring of high 
purity plasmid DNA from E. coli hosts via alkaline lysis.  Between 1 and 3 mL of fresh 
liquid culture of the cells were used as the plasmid source and prepared according to the 
published method.  Improved results were seen by increasing the incubation time when 
adding the final solution for elution from 1 minute to five minutes.  The final plasmid 
DNA was redissolved in 30-50 µL of TE buffer and the concentration was then 
determined with the Nanodrop UV/Vis spectrophotometer. 
 
4.4.1.3             Boiling Minipreps 
 Boiling minipreps are used for crude preparation of plasmid DNA from E. coli, 
typically for use in characteristic digests and for colony screening.  Approximately 1.5 
mL of fresh cell culture were transferred to a microfuge tube, and pelleted at maximum 
speed for five minutes.  The supernatant was removed, and the cells were resuspended in 
a mixture of 300 µL STET with fresh lysozyme (1 mg/mL).  This mixture was then 
incubated 90 seconds at 100 °C and then microfuged at maximum speed for 15 minutes to 
pellet the cell debris.  This cell debris pellet was removed with a toothpick and discarded.  
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Next, the DNA was precipitated by the addition of 300 µL isopropanol and mixed by 
inverting the tube.  The DNA was then pelleted by microcentrifugation at maximum 
speed for 15 minutes.  The supernatant was removed, and the pellet was rinsed with 500-
µL ice cold 70% EtOH. The ethanol was removed, the tube centrifuged 5 minutes at max 
speed, then any remaining EtOH was again removed from the tube.  The tubes were then 
allowed to dry, either upside down at room temperature for 15-20 minutes or on a 37 °C 
heating block for 5-8 minutes.  The resulting DNA was redissolved in 40 µL TE + 0.4 µL 
1 mg/mL heat-treated RNAse A and incubated 15 minutes at 37 °C to destroy any RNA 
contaminants.  The DNA concentration was then determined with the Nanodrop UV/Vis 
spectrophotometer.   
 
4.4.1.4  DNA Extraction from Agarose Gels 
             If recovery of a specific DNA restriction digest band was necessary, the band was 
selected from a 0.8% agarose gel and cleanly excised with a minimal amount of excess 
gel, then extracted using the QIAGEN Qiaex II kit.  The gel slice was transferred into a 
premassed clear plastic tube, and its mass was determined.  As all extracted bands were 
in excess of 4 kb, 3 volumes of buffer QX1 and two volumes of water were added (1 
volume is 100 µL/mg gel).  The QIAEX II resin was resuspended by vortexing 30 
seconds, then an appropriate amount was added to the tube. Where the total DNA was 
less than 2 µg, 10 µL of the QIAEX II were added, while 2-10 µg of DNA resulted in the 
addition of 30 µL of QIAEX II.  The resulting mixture was mixed thoroughly and 
incubated at 50°C for 10 minutes, with vortexing every two minutes to keep the QIAEX 
II in suspension.  The sample was then centrifuged for 30 seconds and the supernatant 
was removed.  The pellet was then washed twice with 500 µL of buffer QX1 to remove 
any residual agarose, then washed twice with 500 µL of buffer PE to remove any salt.  
The pellet was resuspended by vortexing, and then incubated 5 minutes at 50°C.  The 
mixture was then centrifuged one last time, and the removed supernatant contained the 
purified DNA band.   
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4.4.2 PCR Reactions 
 
4.4.2.1  PCR GoTaq Amplification 
 All amplifications were performed according to the published method, using 2/5 of 
the described reaction mixture volume to maximize efficient use of reagents. 
 
Table 11: GoTaq PCR Amplification reaction mixture. 
Component Final Volume (per 
reaction) 
Final Concentration 
5X Green GoTaq reaction 
buffer 
4.0 µL 1X 
dNTPs, 10 mM 0.4 µL of each dNTP 0.2 mM each dNTP 
MgCl2, 25 mM 1.6 µL 1.5 mM MgCl2 
Upstream Primer, 5 mM 2 µL 0.01 µM 
Downstream Primer, 5 mM 2 µL 0.01 µM 
GoTaq DNA Polymerase (5 
U/µL) 
0.1 µL 0.5 U 
Template DNA (<0.5 µg/mL) 1-8 µL Variable 
Nuclease–Free water To 20 µL final volume  
 
Since PCR amplifications tend to be performed in batches to ensure uniform 
concentrations of most reagents, a master mix containing everything except the primers 
and template DNA was made with enough for each trial plus about 10% reserve (e.g. 40 
trials!Master Mix for 44 trials).  This Master Mix was mixed thoroughly. In very large 
cases, such as amplifications with >10 samples with the same primer pair, this Master 
Mix was subdivided into secondary Master Mixes and the primer stocks were added, then 
these were dispensed into PCR tubes.  Otherwise, the Master Mix was distributed to PCR 
tubes, then each had its primers added separately.  Once the Master Mix and primer pairs 
were distributed, the template DNA was added to each tube and they were capped for 
amplification. PCR amplification was performed on an Eppendorf Mastercycler gradient 
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thermocycler under the program GTAQTDOV, shown in Table 12. After completion of 
the amplification run, the product DNA was either used directly or stored in the -20°C 
freezer until use. 
 
Table 12: PCR Program parameters. 
program GTAQTDOV program BIG program HYMUT 
CNTRL TUBE CNTRL TUBE CNTRL BLOCK 
LID=105° LID=105° LID=105° 
NOWAIT AUTO WAIT AUTO NOWAIT AUTO 
1 T=94.0° 00:05:00 1 T=96.0° 00:01:00 1  T=95.0°  0:0:30 
2 T=94.0° 00:00:30 2 T=96.0° 00:00:10 2  T=95.0°  0:0:30 
3 T=65.0° 00:00:30 3 T=50.0° 00:00:05 3  T=55.0°  0:1:00 
      -1.0° +0:00 4 T=60.0° 00:04:00 4  T=68.0°  0:6:00 
      R=3.0°/s +0.0°/s 5 GOTO 2 REP 24 5  GOTO 2 REP 24 
      G=0.0° 6 HOLD 4.0° ENTER 6 HOLD 4.0° ENTER 
4 T=72.0° 00:05:00 end end 
5 GOTO 2 REP 15   
6 T=94.0°  00:00:30   
7 T=50.0° 00:00:30   
8 T=72.0° 00:05:00   
9 GOTO 6 REP 30   
10 T=72.0° 00:05:00   
11 HOLD 4.0° ENTER   
end   
 
4.4.2.2  PCR Mutation 
 Mutation with Quikchange II kit was performed according to the published method, 
while using half of the recommended reaction volume to maximize reagent efficiency. 
The reaction was set up in a PCR tube according to the recipe seen in Table 13 and 
amplified using the program HYMUT, shown in Table 12.  
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Table 13: PCR Mutagenesis reaction mixture. 
Component Final Volume 
10X reaction buffer 2.5 µL 
DNA template (25 ng) Variable, optimal 1-5 µL 
Forward primer (20 ng/µL) 3.125 µL 
Reverse primer (20 ng/µL) 3.125 µL 
dNTP mix 0.5 µL 
H2O To 25 µL 
  
4.4.2.3  PCR Cycle Sequencing 
The procedure was performed according to the kit’s published manual.  The reaction 
was set up in a PCR tube according to the recipe seen in Table 14.  PCR cycle sequencing 
was performed using the program BIG, shown in Table 12.  After completion, the 
products were spun down and transferred to 1.7 mL microcentrifuge tubes. One µL of 1.5 
M NaOAc/ 0.25 M Na2EDTA was added, and the liquid was pipetted to mix.  Next, 40 
µL of room temperature 95% EtOH were added to precipitate the DNA.  The tube was 
flicked to mix, and then centrifuged at maximum speed for 15 minutes.  The supernatant 
was removed, then the tube was spun down a second time for 5 minutes, and the 
remaining supernatant was removed.  Finally, 63 µL of ice cold 70% EtOH were added, 
and the tube was spun once more at maximum speed for 5 minutes.  The supernatant was 
then removed, and the sequencing products were allowed to air dry with heating on a 
37°C block for ~10 min or until dry.  Reactions were shipped to Miami University 
(Xiaoyun Deng, Microbiology) for sequencing by capillary electrophoresis. 
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Table 14: PCR Cycle sequencing reaction mixture 
Component Final Volume 
Template 0.5-5 µL, need 150 ng 
Primer (100 mM) 0.80 µL 
5X Buffer 1.50 µL 
Reaction Mix 1.00 µL 
H2O To 10 µL 
 
4.4.3 DNA Digestion 
 The DNA for digestion was prepared by either a Wizard miniprep or a boiling 
miniprep of a fresh cell culture.  Digestion of the DNA occurred in two recurring scales 
(Table 15).  The buffers used were chosen to provide optimum activity for the enzymes, 
according to the reported values given by NEB.  The resulting fragments were run on 
0.8% agarose gels stained with ethidium bromide for UV visualization. 
 
Table 15:  Standard DNA restriction digest conditions.  Note that analytical digests are designed to 
minimize the amount of enzyme used, while preparative reactions for gel band excision are designed to 
ensure complete digestions. 
Analytical digests Digests for agarose gel band excision 
2.0 µL miniprep DNA ~1 µg DNA in 1-8 µL TE 
2.0 µL NEBuffer 2.0 µL NEBuffer 
2.0 µL BSA (as needed) 2.0 µL BSA (as needed) 
0.5 µL enzyme (each) 1.0 µL enzyme (each) 
Water to 20 µL total volume Water to 20 µL total volume 
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4.4.4  Additional Common Methods 
 
4.4.4.1  Freezer Stocks 
When a valuable plasmid or strain of interest was produced, short-term storage 
options such as Wizard Miniprep DNA solution or regular streak plates were insuficient 
to archive the DNA or cels. To alow for long-term (nearly indefinite) storage, these 
colonies were cultured and prepared using the folowing methods. 
 
4.4.4.1.1  Yeast Freezer Stock Method 
Fresh overnight cultures of the desired strain were incubated overnight to near-
saturation, determined visualy. From each culture, 1 mL was removed and added to 
each of two labeled 2.0-mL conical screw-cap tubes. Next, 80 µL of DMSO was added 
to the dispensed cel culture, and the tubes were sealed and vortexed to mix. The tubes 
were then placed into a prechiled EtOH/dry ice bath and alowed to cool until the cel 
culture was visibly frozen. The tubes were stored at -80 °C. 
 
4.4.4.1.2 E. coli Freezer Stock Method 
Fresh overnight cultures of the desired strain were incubated overnight to near-
saturation, determined visualy. From each culture, 700 µL were removed and added to 
each of two labeled 2.0-mL conical screw-cap tubes. Next, 700 µL of E. coli storage 
bufer (65% glycerol (v/v), 0.1 M MgSO4, and 0.025 M Tris l) was added to the 
dispensed cel culture, and the tubes were sealed and vortexed to mix. The tubes were 
then placed into a prechiled EtOH/dry ice bath and alowed to cool until the cel culture 
was visibly frozen. The tubes were stored in the -80 °C freezer. 
 
4.4.4.1.3 Inoculation from a Freezer Stock 
The freezer stock from the -80 °C freezer was chiled on dry ice. Cels were scraped 
from the top of the freezer stock, either using a sterile 200-µL micropipete tip or a flame-
sterilized inoculation loop and were then inoculated into a culture tube of appropriate 
media, and the fresh inoculation was incubated at 37 °C or 28 °C for E. coli and Y. 
lipolytica, respectively.
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4.4.4.2  Yeast Transformation 
This method is an adaptation of the method of Mauersberger and Nicaud (74).  Three 
flasks of 25 mL YPD were inoculated from a starter of the cells at 5*104, 1*105, and 
2*105 cells/mL and cultured overnight at 28 °C. After ~14-18 hours incubation, 10 mL of 
the culture between 9*107 and 1*108 cells/mL was harvested. The cells were centrifuged 
5 min at 3k rpm, rinsed twice with 10 mL TE, then resuspended at 5*107 cells/mL in 0.1 
M LiOAc, pH 6.0 and incubated one hour at 28°C with gentle shaking.  The cells were 
then centrifuged and resuspended in 1/10th of the volume of 0.1 M LiOAc pH 6.0.  
Carrier DNA (salmon sperm) was incubated at 95 °C for 5 min, and put on ice. Next, 5 
µL carrier DNA, 0.5-1 µg transforming DNA, and 100 µL competent cells were mixed 
and incubated 15 min at 28 °C.  The cells were mixed gently, then 700 µL 40% PEG 
4000 in 0.1 M LiOAc, pH 6.0 was added, and the mixture was again mixed gently.  The 
cells were incubated 1 hour at 28 °C, 250 rpm, then 80 µL DMSO were added and the 
cells were heat shocked in a water bath 10 min at 39 °C.  Lastly, 0.6 mL of 0.1 M LiOAc 
were added twice and mixed by inverting and 200 µL of the transformed cells were 
spread on selective plates. 
 
4.5  Experimental Methods 
 
4.5.1 pCre-AHAS* Assembly 
 
4.5.1.1  Production of pY5-Cre Muta 2E/2S 
The pY5-Cre plasmid and pDONR-AHAS* were provided by Dr. Robert Minto for 
assembly.  Plasmid DNA of pY5-Cre2*-01 was prepared using Wizard miniprep and the 
concentration was checked by Nanodrop.  An EcoRI site was removed by site-directed 
mutagenesis using primers pY5 G2908Cs and pY5 G2908Ca under the HYMUT program.  
The product plasmid was transformed into RbCl2 chemically competent XL1Blue E. coli 
cells and spread on LB+Amp plates.  The plates were incubated overnight at 37 °C, and 8 
colonies were picked and cultured in LB+Amp liquid media at 37°C, 250 rpm.  The 
resulting plasmids were prepared by boiling miniprep, and screened through restriction 
digests with EcoRI.  The four strains containing the proper plasmid were then cultured 
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for fresh growth overnight in LB+Amp, then plasmid DNA was prepared from each 
using the Wizard Miniprep Kit. A segment of the LEU2 gene was then excised through 
digestion with EcoRI and the fragment was ligated to form the plasmid.  The plasmid 
identity was checked by characteristic digests with EcoRI, SphI, EcoRI/SphI, ClaI, SaI, 
SalI, HindIII, NdeI, and SalI/NdeI.  Additionally, the plasmid was sequenced at and 
around the deletion site (primers pY5@4150s, pY5@4900s).  A second EcoRI site was 
mutationally inserted (primers T4309A EcoRI insertion a and T4309A EcoRI insertion s) 
into the pY5-Cre Muta 2S-cut plasmid.  The resulting plasmid DNA was confirmed by 
digestion with EcoRI. 
 
4.5.1.2  Production of the Gateway Entry Clone 
To create the entry clone, 7.0 µL of fresh Muta 2E/2S #6 DNA (207.1 ng/µL) was 
digested with 2.0 µL EcoRI (additionally 1.0 µL NEBuffer EcoRI, 10 µL water) for 2 
hours at 37 °C. The enzyme was heat inactivated 20 minutes at 65 °C, then the digested 
DNA was blunted using the NEB Quick Blunting Kit.  The resulting DNA was purified 
away from the enzymes using a serial phenol/chloroform/isoamyl alcohol extraction.  The 
digest was mixed with 25 µL of equilibrated phenol, vortexed briefly to mix and 
centrifuged to separate the layers.  The phenol (bottom) layer was then removed.  Next, 
12.5 µL of equilibrated phenol and 12.5 µL of a 24:1 chloroform:isoamyl alcohol mixture 
were combined and mixed thoroughly, then added to the blunting reaction.  This new 
mixture was vortexed briefly, spun down to separate the layers, and the organic (bottom) 
layer was removed.  Lastly, 25 µL of 24:1 chloroform:isoamyl alcohol were added, the 
mixture was vortexed, spun down, and the aqueous (top) layer was transferred to a 
separate tube.  The DNA was then precipitated by the addition of 2.26 µL of NaAc and 
60 µL of ice cold 100% EtOH.  The mixture was flicked, then incubated 5 minutes on 
crushed dry ice.  After its incubation, the tube was spun down 5 minutes at maximum 
speed and the supernatant was removed.  One mL of 70% EtOH was added, the tube was 
mixed by inversion, and the sample was centrifuged at maximum speed for 5 minutes.  
The supernatant was removed and the DNA was allowed to dry with light heat at 37 °C. 
The DNA was then redissolved in 17.0 µL water and 2.0 µL of 10X Antarctic 
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phosphatase buffer; 1.0 µL of Antarctic phosphatase (NEB) was added.  The 
modification reaction was incubated 15 minutes at 37 °C, then heat inactivated 15 
minutes at 65 °C.  This blunted and phosphatased product was finally ligated with 
Gateway RfA from the Gateway Kit. 
 
Table 16: Gateway ligation mixture.  Note that the T4 ligase is not provided with the kit and must be 
purchased separately. 
  
 
  
 
 
 
The mixture was combined as described in Table 16, and allowed to incubate for 1 
hour at room temperature.  After ligation was complete, 1 µL of the ligation mixture was 
added to a vial of ccdB survival T1R competent cells and gently mixed.  This tube was 
kept on ice 30 minutes, then heat shocked 30 seconds at 42 °C and returned immediately 
to ice for 2 minutes.  Next, 250 mL of SOC media was added and the tube was incubated 
with shaking 1 hour at 37 °C.  The final transformed cells were spread on LB+Amp+Chl 
prewarmed plates, and incubated at 37 °C. The colonies were screened via growth in 
LB+Amp+Chl media, followed by confirmation of the plasmid by digests MluI and SmaI.  
 
4.5.1.3  The LR Clonase Reaction 
Approximately 0.5 µL of the entry clone AHAS* 11-2 (400.2 ng/µL) was mixed with 
5.0 µL of the destination vector Gateway #9 (35.1 ng/µL) and 2.50 µL TE.  The LR 
Clonase enzyme mix was thawed, vortexed, and 2 µL were added.  After 1 hour 
incubation at room temperature, the solution was treated with 1 µL Proteinase K solution 
and was incubated 10 min at 37 °C.  The product was then transformed into high 
efficiency Omnimax 2 T1R cells per the published method.  The transformed cells were 
then plated on LB+Amp, and the plasmid identity as confirmed by digests with NcoI, 
AflII, and NotI and cycle sequencing into the AHAS* gene using primer pY5@4150s. 
Gateway Ligation Mixture 
5 µL phosphatase-treated DNA 
2 µL Gateway RfA 
2 µL 5X T4 ligase buffer 
1 µL T4 ligase 
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4.5.1.4  Testing CME Concentrations 
Two CME stock solutions were prepared in acetone (50 mg/mL) and ethanol (2.5 
mg/mL).  For growth in liquid media, 25 mL of CM-leu+dex were inoculated with 10 µL 
of a fresh overnight culture of the Yarrowia prototroph (ATCC 20460) and the 
appropriate amount of CME stock (0-250 µg/mL), then incubated at 28 °C, 240 rpm.  For 
each reading  ~500 µL of the culture was removed, diluted as necessary, and quantitated 
using A600 values.  For the solid agar, CM-leu+dex+CME plates were made (0-150 
µg/mL) and freshly cultured Yarrowia prototroph cells (ATCC 20460) were spread on 
the plates. After incubation for 2 days at 28 °C, the resulting colonies were counted 
visually. 
 
4.5.1.5  Testing pCre-AHAS* 
The pCre-AHAS* plasmid was transformed into prototrophic Yarrowia (ATCC 
20460) and spread on CM-leu+dex+CME plates.  The resulting colonies were also 
cultured in liquid CM-leu+dex+CME media.  The presence and identity of the plasmid in 
the surviving colonies was confirmed by rapid plasmid recovery (75) with restriction 
digests of the recovered plasmids.   
The pCre-AHAS* plasmid was also transformed into the Yarrowia ∆FAD2::hph gene 
knockout strain and spread on CM-leu+dex+CME plates. The resulting colonies were 
cultured in liquid CM-leu+dex+CME at 28°C, and then replica plated onto YPD+hyg and 
CM-leu+dex+CME plates.  The presence and identity of pCre-AHAS* was again 
confirmed via rapid plasmid recovery with restriction digests.  Once selected, the final 
colonies were inoculated in triplicate into 5-mL tubes of YPD and incubated 24 hours. 
After incubation, each tube was replicate streaked on YPD and CM-leu+dex+CME plates 
for selection based on loss of pCre-AHAS*, and then inoculated into another tube of 
fresh YPD for another round of growth.  After obtaining the new Yarrowia ∆FAD2 
without pCre-AHAS*, this final strain was cultured in YPD overnight at 28 °C, 240 rpm. 
Approximately 1 mL of this culture was harvested for the preparation of FAMEs. The 
supernatant was removed from the culture, then the cells were washed twice with water 
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and brought up in 1 mL 2% H2SO4 in MeOH. The tubes were tightly capped and 
incubated 1 hr at 80 °C, then 1 mL of water was added and the FAMEs were extracted 
twice with 2-3 mL of hexanes.  The hexanes mixture was evaporated to dryness by 
heating under a steady stream of nitrogen, then redissolved in 200 µL of hexanes and 
analyzed by GC-MS. 
 
4.5.2 Lipid Degradation with POX Knockouts 
 
4.5.2.1  Preparation 
Stocks of all fatty acids in use were prepared at 50 µM in DMSO, and stored at -80 °C 
to limit air oxidation.  The Yarrowia ∆POX2::hph strain was obtained from Dr. Brenda 
Blacklock, and the positioning of the knockout construct in the gDNA was confirmed by 
PCR amplification of HPH3!Pox2 C, Pox2 A5!Pox2 C, and HPH3 !Pox2 F2.  Since 
quantitation of lipids in the media and washes was required, the maximum concentration 
of Tergitol NP-40 that allowed for proper extraction with hexanes was determined via 
serial dilution with attempted extraction.  FAMEs were prepared of each of the fatty acids 
to be fed, to determine location in the resulting spectra.  Additionally, the area of the peak 
relative to FAME present was determined for the 11-Br 11:0 internal standard. 
 
4.5.2.2  Feedings 
Fresh starter stocks of the Yarrowia prototroph and ∆POX2::hph were incubated in 
YPD overnight at 28 °C, 240 rpm.  Each 3-mL feeding culture was grown in YPD+0.1% 
NP-40 inoculated with 30 µL of the 50 mM fatty acid stock, and 30 µL of the starter 
culture.  The feedings were incubated 24 hours at 28 °C, 240 rpm, and then prepared as 
FAMEs. About 0.25 mL of each culture was harvested, then washed twice with 0.25 mL 
of 0.1% NP-40, and twice with 0.25 mL H2O. The washes were stored in a separate 
FAME tube.  The cells were then brought up with 1 mL of 2% H2SO4 in MeOH and 
spiked with 5 µL of the 11-Br 11:0 internal standard. The tubes were tightly capped and 
incubated 1 hr at 80 °C, then 1 mL of water was added and the FAMEs were extracted 
twice with 2-3 mL of hexanes.  The hexanes mixture was evaporated to dryness by 
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heating under a steady stream of nitrogen, then redissolved in 200-500 µL of hexanes and 
analyzed by GC-MS.  Next, the wash solutions were diluted with ~ 1.75 mL of H2O, 
spiked with 5 µL of the 11-Br 11:0 internal standard, and extracted twice with ~3-4 mL 
of hexanes.  The resulting solution was evaporated to dryness with heating under a stream 
of nitrogen, then redissolved in 1 mL 2% H2SO4 in MeOH. The tubes were tightly capped 
and incubated 1 hr at 80 °C, then 1 mL of water was added and the FAMEs were 
extracted twice with 2-3 mL of hexanes.  The hexanes mixture was evaporated to dryness 
by heating under a steady stream of nitrogen, then redissolved in 200-500 µL of hexanes 
and analyzed by GC-MS. 
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Appendix A pCre-AHAS* Primers, Sequences, and GC/MS 
 
Table 17: FAD2 Knockout primer list 
Primer 
Name 
Sequence (From 5’ to 3’) 
Fad2-A1 AGG TGT TTC GGA AGA AGG TAT T 
Fad2-A2 GTA TAG CAT ACA TTA TAC GAA CGG TAA 
GCT AGA AAT GTT ATT TGA T 
Fad2-B1 GTA TAA TGT ATG CTA TAC GAA CGG TAT 
TCT ATG GTC GGT CTG TT 
Fad2-B2 CGG CGG CAG GCA GGC AGA CCA A 
Fad2-C GTG GCG GTT AGG AGA GGC GGG G 
Fad2-E AGG TGC TCT CCT AGT CTG AAC T 
Fad 2-F CCG TTC CTG TAG CGG GCG GTT G 
D1 TAC CGT TCG TAT AAT GTA TGC TAT ACG 
AAG TTA TAG AGA CCG GGT TGG CGG C 
A1’ TTA GAA GTG AGC TGT CCA AGG TCG CA 
A2’ AGC TAG AAA TGT TAT TTG ATT GTG TT 
D2 TAC CGT TCG TAT AGC ATA CAT TAT ACG 
AAG TTA TTT TAC AAC AAT ATC TGG T 
HPH1 GAC CTG CCT GAA ACC GAA CTG C 
HPH2 ATG CCT CCG CTC GAA GTA GCG C 
 
  
94 
 
Table 18: pY5-Cre Sequencing and Mutagenesis primers. Note that the location for sequencing primers is 
based on the position in the original pY5-Cre plasmid, prior to excision or Gateway insertion (see Figure 
15) 
  
Primer Name Amplification Use Sequence (From 5’ to 3’) 
pY5@1s Sequencing GGT GGA GCT CCA GCT TTT GT 
pY5@1a Sequencing ACA AAA GCT GGA GCT CCA CC 
pY5@700s Sequencing GCT CCA AGC TGG GCT GTG TG 
pY5@1400s Sequencing AAA CCA GCC AGC CGG AAG GG 
pY5@2100s Sequencing TAT TAT TGA AGC ATT TAT CA 
pY5@2800s Sequencing GTC ACG ACG TTG TAA AAC GA 
pY5@3500s Sequencing GAT TAT TAT TGG ACG AGA AT 
pY5@4150s Sequencing GTA TAC CTA CTT GTA CTT GT 
pY5@4900s Sequencing TCC ACT ACA AAC ACA CCC AA 
pY5@5600s Sequencing GCA CGT TGG CCT TGT CAA GA 
pY5@6300s Sequencing CGC ACT TTT GCC CGT GCT AT 
pY5 G2908Cs Mutagenesis, ∆EcoRI site CGA TAA GCT TGA TAT CCA ATT 
CAT GTC ACA CA 
pY5 G2908Ca Mutagenesis, ∆EcoRI site TGT GTG ACA TGA ATT GGA TAT 
CAA GCT TAT CG 
pY5-leu@4201s Sequencing ATA GAC TTA TGA ATC TGC ACG 
G 
pY5-leu@4378a Sequencing TCA ATT TGG GGT CAA TTG GGG 
CAA 
C4296G SphI 
insertion-s Mutagenesis, 
::SphI site 
GGA TCT GTT CGG AAA TCA ACG 
CAT GCT CAA CCG AT 
C4296G SphI 
insertion-a 
Mutagenesis, 
::SphI site 
ATG GGT TGA GCA TGC GTT GAT 
TTC CGA ACA GAT CC 
pY5-leu repair s Mutagenesis TTG ACC TTG TTG GCA ACA AGT 
CTC CGA CCT CGG AGG TGG 
pY5-leu repair a Mutagenesis CCA CCT CCG AGG TCG GAG ACT 
TGT TGC CAA CAA GGT CAA 
pY5Cre 
polylinker-s 
Original linker to 
preserve ARS18 
CTA CTT GGG TGT AAT ATT GGG 
ATC TGT TCG GCT AGC GTT TAA 
ACG 
pY5Cre-
polylinker-a 
Original linker to 
preserve ARS18 
AAT TCG TTT AAA CGC TAG CCG 
AAC AGA TCC CAA TAT TAC ACC 
CAA GTA GCA TG 
T4309A EcoRI 
insertion-s Mutagenesis,  
::EcoRI site 
ATG CTC AAC CGA ATT CGA CAG 
TAA TAA TTT GAA TC 
T4309A EcoRI 
insertion-a Mutagenesis,  
::EcoRI site 
GAT TCA AAT TAT TAC TGT CGA 
ATT CGG TTG AGC AT 
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Table 19: Cre recombinase and AHAS Sequencing and Mutagenesis primers.	  
Primer Name Amplification Use Sequence (From 5’ to 3’) 
Cre – seq 1 Sequencing ACA TGT CCA TCA GGT TCT TGC G 
Cre – seq 2 Sequencing CCC GCG CTG GAG TTT CAA TAC C 
Cre – As PCR 
Amplification 
CAA AGG ATC CGG CAT ATG TCC 
AAT TTA CTG ACC GTA CAC C 
Cre – Aa PCR 
Amplification 
CCG CGG TGG CGG CCG CCC ATG 
GCT AAT CGC CAT CTT CCA GCA 
GGC GCA 
Cre – Bs  Mutagenesis, 
∆BamHI site 
ATG CGG CGA ATC CGA AAA GAA 
AAC 
Cre – Ba Mutagenesis, 
∆BamHI site 
CGT TTT CTT TTC GGA TTC GCC 
GCA T 
AHAS – As PCR 
Amplification 
GGG GAC AAG TTT GTA CAA AAA 
AGC AGG CTT TCC CTA GTC CCA 
GTG TAC ACC CGC 
AHAS – Aa PCR 
Amplification 
AGA GAG ACT GCA GCT GGG TGA 
CCA T 
AHAS – Bs PCR 
Amplification 
ATG GTC ACC CAG CTG CAG TCT 
CTC T 
AHAS – Ba PCR 
Amplification 
GGG GAC CAC TTT GTA CAA GAA 
AGC TGG GTG AGG TGT GCT GGA 
TTC ATG ACC ACA 
AHAS – Seq 1 Sequencing GTC GGG CGA GTC GCG ATT GCA 
TGT T 
AHAS – Seq 2 Sequencing ACG TCC ACC AGA CCA CCT TTG 
AGA A 
AHAS – Seq 3 Sequencing CGA CAC CCT CGA ACC ATG ATC 
ACT T 
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Nucleotide Sequence for AHAS from Yarrowia lipolytica 
ATGCAATCGCGACTCGCCCGACGGGCCACTAACCTGGCCAGAATCTCCAGAT
CCAAGTATTCTCTTGGTCTGCGATATGTTTCCAACACAAAAGCCCCTGCTGCC
CAGCCGGCAACTGCTGAGTGAGTATTCCTTGCCATAAACGACCCAGAACCAC
TGTATAGTGTTTGGAAGCACTAGTCAGAAGACCAGCGAAAACAGGTGGAAA
AAACTGAGACGAAAAGCAACGACCAGAAATGTAATGTGTGGAAAAGCGACA
CACACAGAGCAGATAAAGAGGTGACAAATAACGACAAATGAAATATCAGTA
TCTTCCCACAATCACTACCTCTCAGCTGTCTGAAGGTGCGGCTGATATATCCA
TCCCACGTCTAACGTATGGAGTGTGATAGAATATGACGACACAAGCATGAGA
ACTCGCTCTCTATCCAACCACCGAAACACTGTCACTACAGCCGTTCTTGTTGC
TCCATTCGCTTTTGTGATTCCATGCCTTCTCTGGTGACTGACAACATTCCTTCC
TTTTCTCCAGCCCTGTTGTTATCTGCTCATGACCTACGGCCACTCTCTATCGCA
TACTAACATAGACGATCCCAGCCCGCTCCCCACTTCCAGGGCACCGTTGGCA
AGCCTCCTATCCTCAAGAAGGCTGAGGCTGCCAACGCTGACATGGACGAGTC
CTTCATCGGAATGTCTGGAGGAGAGATCTTCCACGAGATGATGCTGCGACAC
AACGTCGACACTGTCTTCGGTTACCCCGGTGGAGCCATTCTCCCCGTCTTTGA
CGCCATTCACAACTCTGAGTACTTCAACTTTGTGCTCCCTCGACACGAGCAGG
GTGCCGGCCACATGGCCGAGGGCTACGCTCGAGCCTCTGGTAAGCCCGGTGT
CGTTCTCGTCACCTCTGGCCCCGGTGCCACCAACGTCATCACCCCCATGCAGG
ACGCTCTTTCCGATGGTACCCCCATGGTTGTCTTCACCGGTCAGGTCCTGACC
TCCGTTATCGGCACTGACGCCTTCCAGGAGGCCGATGTTGTCGGCATCTCCCG
ATCTTGCACCAAGTGGAACGTCATGGTCAAGAACGTTGCTGAGCTCCCCCGA
CGAATCAACGAGGCCTTTGAGATTGCTACTTCCGGCCGACCCGGTCCCGTTCT
CGTCGATCTGCCCAAGGATGTTACTGCTGCCATCCTGCGAGAGCCCATCCCCA
CCAAGTCCACCATTCCCTCGCATTCTCTGACCAACCTCACCTCTGCCGCCGCC
ACCGAGTTCCAGAAGCAGGCTATCCAGCGAGCCGCCAACCTCATCAACCAGT
CCAAGAAGCCCGTCCTTTACGTCGGACAGGGTATCCTTGGCTCCGAGGAGGG
TCCTAAGCTGCTTAAGGAGCTGGCTGAGAAGGCCGAGATTCCCGTCACCACT
ACTCTGCAGGGTCTTGGTGCCTTTGACGAGCGAGACCCCAAGTCTCTGCACAT
GCTCGGTATGCACGGTTCCGGCTACGCCAACATGGCCATGCAGAACGCTGAC
TGTATCATTGCTCTCGGCGCCCGATTTGATGACCGAGTTACCGGCTCCATCCC
CAAGTTTGCCCCCGAGGCTCGAGCCGCTGCCCTTGAGGGTCGAGGTGGTATT
GTTCACTTTGAGATCCAGGCCAAGAACATCAACAAGGTTGTTCAGGCCACCG
AAGCCGTTGAGGGAGACGTTACCGAGTCTGTCCGACAGCTCATCCCCCTCAT
CAACAAGGTCTCTGCCGCTGAGCGAGCTCCCTGGACTGAGACTATCCAGTCC
TGGAAGCAGCAGTTCCCCTTCCTCTTCGAGGCTGAAGGTGAGGATGGTGTTAT
CAAGCCCCAGTCCGTCATTGCTCTGCTCTCTGACCTGACAGAGAACAACAAG
GACAAGACCATCATCACCACCGGTGTTGGTCAGCATCAGATGTGGACTGCCC
AGCATTTCCGATGGCGACACCCTCGAACCATGATCACTTCTGGTGGTCTTGGA
ACTATGGGTTACGGCCTGCCCGCCGCTATCGGCGCCAAGGTTGCCCGACCTG
ACTGCGACGTCATTGACATCGATGGTGACGCTTCTTTCAACATGACTCTGACC
GAGCTGTCCACCGCCGTTCAGTTCAACATTGGCGTCAAGGCTATTGTCCTCAA 
CAACGAGGAACAGGGTATGGTCACCCAGCTGCAGTCTCTCTTCTACGAGAAC
CGATACTGCCACACTCATCAGAAGAACCCCGACTTCATGAAGCTGGCCGAGT
CCATGGGCATGAAGGGTATCCGAATCACTCACATTGACCAGCTGGAGGCCGG
97 
 
TCTCAAGGAGATGCTCGCATACAAGGGCCCTGTGCTCGTTGAGGTTGTTGTCG
ACAAGAAGATCCCCGTTCTTCCCATGGTTCCCGCTGGTAAGGCTTTGCATGAG
TTCCTTGTCTACGACGCTGACGCCGAGGCTGCTTCTCGACCCGATCGACTGAA
GAATGCCCCCGCCCCTCACGTCCACCAGACCACCTTTGAGAACTAA 
 
Predicted translation of coding sequence for AHAS from Y. lipolytica: 
MQSRLARRATNLARISRSKYSLGLRYVSNTKAPAAQPATAE.VFLAINDPEPLYSV
WKH.SEDQRKQVEKTETKSNDQKCNVWKSDTHRADKEVTNNDK.NISIFPQSLPL
SCLKVRLIYPSHV.RMECDRI.RHKHENSLSIQPPKHCHYSRSCCSIRFCDSMPSLVT
DNIPSFSPALLLSAHDLRPLSIAY.HRRSQPAPHFQGTVGKPPILKKAEAANADMD
ESFIGMSGGEIFHEMMLRHNVDTVFGYPGGAILPVFDAIHNSEYFNFVLPRHEQG
AGHMAEGYARASGKPGVVLVTSGPGATNVITPMQDALSDGTPMVVFTGQVLTS
VIGTDAFQEADVVGISRSCTKWNVMVKNVAELPRRINEAFEIATSGRPGPVLVDL
PKDVTAAILREPIPTKSTIPSHSLTNLTSAAATEFQKQAIQRAANLINQSKKPVLYV
GQGILGSEEGPKLLKELAEKAEIPVTTTLQGLGAFDERDPKSLHMLGMHGSGYA
NMAMQNADCIIALGARFDDRVTGSIPKFAPEARAAALEGRGGIVHFEIQAKNINK
VVQATEAVEGDVTESVRQLIPLINKVSAAERAPWTETIQSWKQQFPFLFEAEGED
GVIKPQSVIALLSDLTENNKDKTIITTGVGQHQMWTAQHFRWRHPRTMITSGGL
GTMGYGLPAAIGAKVARPDCDVIDIDGDASFNMTLTELSTAVQFNIGVKAIVLNN
EEQGMVTQLQSLFYENRYCHTHQKNPDFMKLAESMGMKGIRITHIDQLEAGLKE
MLAYKGPVLVEVVVDKKIPVLPMVPAGKALHEFLVYDADAEAASRPDRLKNAP
APHVHQTTFEN 
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Nucleotide sequence for Cre recombinase 
ATGTCCAATTTACTGACCGTACACCAAAATTTGCCTGCATTACCGGTCGATGC
AACGAGTGATGAGGTTCGCAAGAACCTGATGGACATGTTCAGGGATCGCCAG
GCGTTTTCTGAGCATACCTGGAAAATGCTTCTGTCCGTTTGCCGGTCGTGGGC
GGCATGGTGCAAGTTGAATAACCGGAAATGGTTTCCCGCAGAACCTGAAGAT
GTTCGCGATTATCTTCTATATCTTCAGGCGCGCGGTCTGGCAGTAAAAACTAT
CCAGCAACATTTGGGCCAGCTAAACATGCTTCATCGTCGGTCCGGGCTGCCA
CGACCAAGTGACAGCAATGCTGTTTCACTGGTTATGCGGCGAATCCGAAAAG
AAAACGTTGATGCCGGTGAACGTGCAAAACAGGCTCTAGCGTTCGAACGCAC
TGATTTCGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGAT
ATACGTAATCTGGCATTTCTGGGGATTGCTTATAACACCCTGTTACGTATAGC
CGAAATTGCCAGGATCAGGGTTAAAGATATCTCACGTACTGACGGTGGGAGA
ATGTTAATCCATATTGGCAGAACGAAAACGCTGGTTAGCACCGCAGGTGTAG
AGAAGGCACTTAGCCTGGGGGTAACTAAACTGGTCGAGCGATGGATTTCCGT
CTCTGGTGTAGCTGATGATCCGAATAACTACCTGTTTTGCCGGGTCAGAAAAA
ATGGTGTTGCCGCGCCATCTGCCACCAGCCAGCTATCAACTCGCGCCCTGGA
AGGGATTTTTGAAGCAACTCATCGATTGATTTACGGCGCTAAGGATGACTCTG
GTCAGAGATACCTGGCCTGGTCTGGACACAGTGCCCGTGTCGGAGCCGCGCG
AGATATGGCCCGCGCTGGAGTTTCAATACCGGAGATCATGCAAGCTGGTGGC
TGGACCAATGTAAATATTGTCATGAACTATATCCGTACCCTGGATAGTGAAA
CAGGGGCAATGGTGCGCCTGCTGGAAGATGGCGATTAG 
 
Predicted translation of coding sequence for Cre recombinase 
MSNLLTVHQNLPALPVDATSDEVRKNLMDMFRDRQAFSEHTWKMLLSVCRSW
AAWCKLNNRKWFPAEPEDVRDYLLYLQARGLAVKTIQQHLGQLNMLHRRSGLP
RPSDSNAVSLVMRRIRKENVDAGERAKQALAFERTDFDQVRSLMENSDRCQDIR
NLAFLGIAYNTLLRIAEIARIRVKDISRTDGGRMLIHIGRTKTLVSTAGVEKALSLG
VTKLVERWISVSGVADDPNNYLFCRVRKNGVAAPSATSQLSTRALEGIFEATHR
LIYGAKDDSGQRYLAWSGHSARVGAARDMARAGVSIPEIMQAGGWTNVNIVM
NYIRTLDSETGAMVRLLEDGD 
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Figure 42: Yarrowia prototroph GC/MS total ion chromatogram with oleic acid MS. 
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Figure 43: Yarrowia prototroph GC/MS total ion chromatogram with linoleic acid MS. 
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Figure 44: Yarrowia ∆FAD2 #1 GC/MS total ion chromatogram with oleic acid MS. 
  
102 
 
 
Figure 45: Yarrowia ∆FAD2 #2 GC/MS total ion chromatogram with oleic acid MS 
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Figure 46: Yarrowia ∆FAD2 #3 GC/MS total ion chromatogram with oleic acid MS 
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Appendix B Yarrowia Knockout Construct Primers 
 
Table 20: POX2 Knockout primer list 
Primer 
Name 
Amplification Use Sequence (From 5’ to 3’) 
Pox2-A2-
IScel 
Amplification from 
gDNA 
CTA TAT TAC CCT GTT ATC CCT AGC GTA 
ACT GGC GTC GTT GCT TGT GTG ATT TTT 
GA 
Pox2-B1-
IScel 
Amplification from 
gDNA 
AGT TAC GCT AGG GAT AAC AGG GTA ATA 
TAG TAG ACA AGC GGG TAT TTA TTG TAT 
GA 
Pox2-A3 PCR amplification GAT TCC GCC AAG TGA GAC TGG CGA TC 
Pox2-A5 Verification of 
construct position 
CCC TGG CTT GGA GAT GGT CGG TCC AT 
Pox2-B4 PCR amplification TCG ACA AGT ATT TGC GGT AAT TTG GG 
Pox2-B6 Verification of 
construct position 
TCG GTT GTT CAG AAG AGC ATA TGG CA 
Pox2-C Verification of 
construct position 
CCG GTT CGA TTC CGG TGT CGT CCA AT 
Pox2-E Verification of 
construct position 
CCG CCT CTT TGT TTG GTT TTT TTT CT 
Pox2-F Verification of 
construct position 
TAA CAG TAC ACG ATT CAA CCA TAG CA 
Pox2-F2 Verification of 
construct position 
TAT AAT ACA TAC ATA TAT TAA CAG TA 
HPH3 Verification of 
construct position 
GAC CTG CCT GAA ACC GAA CTG C 
HPH4 Verification of 
construct 
ATG CCT CCG CTC GAA GTA GCG C 
HPH3.1 PCR amplification GTA CAC AAA TCG CCC GCA GAA GCG CG 
HPH4.1 PCR amplification GAA GCT GAA AGC ACG AGA TTC TTC GC 
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Table 21: Pox3 Knockout primer list 
Primer 
Name 
Amplification Use Sequence (From 5’ to 3’) 
Pox3-A2-
IScel 
Amplification 
from gDNA 
CTA TAT TAC CCT GTT ATC CCT AGC GTA 
ACT TGT GTG TAT CGT AGA GGT AGT GAC 
GT 
Pox3-B1-
IScel 
Amplification 
from gDNA 
AGT TAC GCT AGG GAT AAC AGG GTA ATA 
TAG TAG ATG GAG CGT GTG TTC TGA GTC 
GA 
Pox3-A3 PCR amplification TAG TGT TTT TGT TGG TTT TTA TTT GA 
Pox3-A5 Verification of 
construct position 
CGG AAA AAT AGG GGG AAA AGA CGC AA 
Pox3-B4 PCR amplification GCT CAT TTT CGG TCT CCA AAC TGA TT 
Pox3-B6 Verification of 
construct position 
ATT TCT TGA CCT CAT CAA TGA CTT CT 
Pox3-C Verification of 
construct position 
GGG CTC TTT ATC TCG AAT CAT GGT GG 
Pox3-E Verification of 
construct position 
GCT GTT CGG TCG ATA GTC GGA GCT GT 
Pox3-F Verification of 
construct position 
GAC AAC TTC TAA GAC ATG TCC TGG TT 
HPH3 Verification of 
construct position 
GAC CTG CCT GAA ACC GAA CTG C 
HPH4 Verification of 
construct position 
ATG CCT CCG CTC GAA GTA GCG C 
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Appendix C Other Relevant Plasmid Maps and Information 
 
  
 
 
Figure 47: Map of the pDONR221 donor vector used for the BP Clonase reaction. Map courtesy of 
Life Technologies (70)  
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Figure 48: Invitrogen 1kb DNA Extension Ladder documentation 
 
 
 
